

TEKLA LIFE SCIENCES INVESTORS
Form N-PX
August 20, 2018

**UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION**

OMB APPROVAL
OMB Number: 3235-0582
Expires: March 31, 2021
Estimated average burden
hours per response.....7.2

Washington, D.C. 20549

FORM N-PX

**ANNUAL REPORT OF PROXY VOTING RECORD OF REGISTERED
MANAGEMENT INVESTMENT COMPANY**

Investment Company Act file number **811- 06565**

Tekla Life Sciences Investors

(Exact name of registrant as specified in charter)

100 Federal Street, 19th Floor, Boston, MA
(Address of principal executive offices)

02110
(Zip code)

Laura Woodward

Tekla Life Sciences Investors

100 Federal Street, 19th Floor, Boston MA 02110

(Name and address of agent for service)

Registrant's telephone number, including area code: **617-772-8500**

Date of fiscal year end: **September 30**

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Date of reporting period: **7/1/17-6/30/18**

Form N-PX is to be used by a registered management investment company, other than a small business investment company registered on Form N-5 (ss.ss.239.24 and 274.5 of this chapter), to file reports with the Commission, no later than August 31 of each year, containing the registrant's proxy voting record for the most recent twelve-month period ended June 30, pursuant to section 30 of the Investment Company Act of 1940 and rule 30b1-4 thereunder (17 CFR 270.30b1-4). The Commission may use the information provided on Form N-PX in its regulatory, disclosure review, inspection, and policymaking roles.

A registrant is required to disclose the information specified by Form N-PX, and the Commission will make this information public. A registrant is not required to respond to the collection of information contained in Form N-PX unless the Form displays a currently valid Office of Management and Budget (OMB) control number. Please direct comments concerning the accuracy of the information collection burden estimate and any suggestions for reducing the burden to the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW, Washington, DC 20549-0609. The OMB has reviewed this collection of information under the clearance requirements of 44 U.S.C. ss. 3507.

Item 1. Proxy Voting Record.

*HQL Vote Summary***AC IMMUNE SA**

Security	H00263105	Meeting Type	Special
Ticker Symbol	ACIU	Meeting Date	27-Apr-2018
Record Date	13-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	In the event that at the Extraordinary Shareholders Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
2.A	Election of Douglas Williams as Member to the Board of Directors	Management	For	N/A
2.B	Election of Douglas Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
3.a	Vote on Total Non-Performance-Related Compensation for the new Member of the Board of Directors from 27 April 2018 to 30 June 2018	Management	For	N/A
3.b	Vote on Equity for the new Member of the Board of Directors	Management	For	N/A
4.a	Share Capital Increase for Institutional Investors	Management	For	N/A
4.b	Share Capital Increase for Current Shareholders	Management	For	N/A

AC IMMUNE SA

Security Ticker Symbol Record Date	H00263105 ACIU 23-May-2018	Meeting Type Meeting Date	Annual 06-Jul-2018
---	----------------------------------	--------------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
A.	In the event that at the Annual General Meeting, shareholders or the Board of Directors make additional or amended motions to the published agenda items and/or put forward new motions or in absence of any specific instruction, I/we instruct the independent proxy to vote in respect to such motions as proposed by the Board of Directors	Management	For	N/A
1.	Approval of the Annual Report, Annual Statutory Financial Statements and Financial Statements under IFRS of AC Immune SA for the year 2017	Management	For	N/A
2.	Appropriation of Loss	Management	For	N/A
3.	Discharge of the Members of the Board of Directors and the Executive Committee	Management	For	N/A
4a.	Vote on Total Non-Performance-Related Compensation for Members of the Board of Directors from 1 July 2018 to 30 June 2019	Management	For	N/A
4b.	Vote on Equity for Members of the Board of Directors	Management	For	N/A
4c.	Vote on Total Non-Performance-Related Compensation for Members of the Executive Committee from 1 July 2018 to 30 June 2019	Management	For	N/A
4d.	Vote on Total Variable Compensation for Members of the Executive Committee for the current year 2018	Management	For	N/A
4e.	Vote on Equity for Members of the Executive Committee	Management	For	N/A
5a.	Re-election of Martin Velasco as member and Chairman of the Board of Directors	Management	For	N/A
5b.	Re-election of Peter Bollmann as the Member of the Board	Management	For	N/A
5c.	Re-election of Friedrich von Bohlen as the Member of the Board	Management	For	N/A
5d.	Re-election of Andrea Pfeifer as the Member of the Board	Management	For	N/A
5e.	Re-election of Detlev Riesner as the Member of the Board including granting an exception to the age limit	Management	For	N/A
5f.	Re-election of Tom Graney as the Member of the Board	Management	For	N/A
5g.	Re-election of Douglas Williams as the Member of the Board	Management	For	N/A
5h.	Election of Werner Lanthaler as the Member of the Board	Management	For	N/A
6a.	Re-election of Tom Graney to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6b.	Re-election of Martin Velasco to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
6c.	Re-election of Doug Williams to the Compensation, Nomination & Corporate Governance Committee	Management	For	N/A
7.	Re-election of the independent proxy Bugnion Ballansat Ehrler, represented by Gerald Virieux, avocat, Geneva	Management	For	N/A
8.	Election of the Auditors, PricewaterhouseCoopers SA, Pully	Management	For	N/A
9a.	Share Capital Increase for Institutional Investors	Management	For	N/A
9b.	Share Capital Increase for Current Shareholders	Management	For	N/A

ACADIA PHARMACEUTICALS INC.

Security	004225108	Meeting Type	Annual
Ticker Symbol	ACAD	Meeting Date	06-Jun-2018
Record Date	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Julian Baker		For	For
	2 Stephen Biggar, M.D PhD		For	For
	3 Daniel Soland		For	For
2.	To approve an amendment to our 2010 Equity Incentive Plan, as amended, to, among other things, increase the aggregate number of shares of common stock authorized for issuance under the plan by 6,700,000 shares.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement for the annual meeting.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ACCELERON PHARMA INC.

Security	00434H108	Meeting Type	Annual
Ticker Symbol	XLRN	Meeting Date	06-Jun-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Habib J. Dable	Management	For	For
1b.	Election of Class II Director: Terrence C. Kearney	Management	For	For
1c.	Election of Class II Director: Karen L. Smith, M.D., Ph.D.	Management	For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ACHILLION PHARMACEUTICALS INC

Security	00448Q201	Meeting Type	Annual
Ticker Symbol	ACHN	Meeting Date	31-May-2018
Record Date	16-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Nominee removed		For	For
	2 Jason Fisherman, M.D.		For	For
2.	To approve, on an advisory basis, our executive compensation.	Management	For	For
3.	To approve an amendment and restatement of our 2015 Stock Incentive Plan.	Management	For	For
4.	To ratify the selection of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the current fiscal year.	Management	For	For
5a.	To elect one Class III Director for a term to expire at our 2021 annual meeting of stockholders or until his successor is duly elected and qualified: Joseph Truitt	Management	For	For

ADAMAS PHARMACEUTICALS, INC.

Security	00548A106	Meeting Type	Annual
Ticker Symbol	ADMS	Meeting Date	06-Jun-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 William W. Ericson		For	For
	2 Martha J. Demski		For	For
	3 Ivan Lieberburg MD PhD		For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

ADAPTIMMUNE THERAPEUTICS PLC

Security	00653A107	Meeting Type	Annual
Ticker Symbol	ADAP	Meeting Date	20-Jun-2018
Record Date	03-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect as a director, Lawrence Alleva, who retires by rotation in accordance with the Articles of Association.	Management	For	For
2.	To re-elect as a director, David Mott, who retires by rotation in accordance with the Articles of Association.	Management	For	For
3.	To re-elect as a director, Elliott Sigal, who retires by rotation in accordance with the Articles of Association.	Management	For	For
4.	To re-appoint KPMG LLP as our U.K. statutory auditors under the U.K. Companies Act 2006, to hold office until the conclusion of the next general meeting of shareholders at which the U.K. statutory accounts and reports are presented.	Management	For	For
5.	To authorize the Audit Committee to determine our U.K. statutory auditors remuneration for the fiscal year ending December 31, 2018.	Management	For	For
6.	To receive the U.K. statutory annual accounts and reports for ...(Due to space limits, see proxy material for full proposal).	Management	For	For
7.	To receive and approve our U.K. statutory directors remuneration report for the year ended December 31, 2017.	Management	For	For
8.	To receive and approve our Directors Remuneration Policy, which, if approved, will take effect upon conclusion of the Annual General Meeting.	Management	For	For

AFFIMED N.V

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	N01045108	Meeting Type	Annual
Ticker Symbol	AFMD	Meeting Date	19-Jun-2018
Record Date	22-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
5	Discussion of the 2017 Statutory Annual Report and proposal to adopt the financial statements for the financial year 2017, as prepared in accordance with Dutch law	Management	For	For
7	Amendment of the Remuneration Policy for the Supervisory Board (the SB Remuneration Policy)	Management	For	For
8	Discharge of the managing directors for their management during the financial year 2017	Management	For	For
9	Discharge of the supervisory directors for their supervision during the financial year 2017	Management	For	For
10a	Appointment of: Dr. Mathieu Simon as a supervisory director	Management	For	For
10b	Reappointment of: Dr. Ulrich M. Grau as a supervisory director	Management	For	For
11	Appointment of the auditor for the financial year 2018	Management	For	For
12	Amendment of the articles of association	Management	For	For
13	Authorization to acquire shares	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AGIOS PHARMACEUTICALS, INC.

Security	00847X104	Meeting Type	Annual
Ticker Symbol	AGIO	Meeting Date	31-May-2018
Record Date	10-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Kaye Foster		For	For
	2 Maykin Ho, Ph.D.		For	For
	3 John M. Maraganore, PhD		For	For
2.	To vote, on an advisory basis, to approve named executive officer compensation.	Management	For	For
3.	To ratify the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

AKEBIA THERAPEUTICS, INC.

Security	00972D105	Meeting Type	Annual
Ticker Symbol	AKBA	Meeting Date	14-Jun-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Michael D. Clayman		For	For
	2 Duane Nash		For	For
	3 Ronald C. Renaud, Jr.		For	For
	4 John P. Butler		For	For
	5 Muneer A. Satter		For	For
	6 Michael S. Wyzga		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ALBIREO PHARMA INC.

Security	01345P106	Meeting Type	Annual
Ticker Symbol	ALBO	Meeting Date	08-Jun-2018
Record Date	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	Ronald H.W. Cooper		For	For
2	Anne Klibanski, M.D.		For	For
3	Stephanie S. Okey, M.S.		For	For
2.	To approve the Albireo Pharma, Inc. 2018 Equity Incentive Plan.	Management	For	For
3.	To approve the Albireo Pharma, Inc. 2018 Employee Stock Purchase Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as Albireo's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ALDER BIOPHARMACEUTICALS, INC.

Security	014339105	Meeting Type	Annual
Ticker Symbol	ALDR	Meeting Date	23-May-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Paul B. Cleveland		For	For
	2 Stephen M. Dow		For	For
	3 A. Bruce Montgomery		For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the accompanying proxy statement.	Management	For	For
3.	To ratify the selection by the Audit Committee of the Board of Directors of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

ALEXION PHARMACEUTICALS, INC.

Security	015351109	Meeting Type	Annual
Ticker Symbol	ALXN	Meeting Date	08-May-2018
Record Date	12-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Felix J. Baker		For	For
	2 David R. Brennan		For	For
	3 Christopher J. Coughlin		For	For
	4 Deborah Dunsire		For	For
	5 Paul A. Friedman		For	For
	6 Ludwig N. Hantson		For	For
	7 John T. Mollen		For	For
	8 Francois Nader		For	For
	9 Judith A. Reinsdorf		For	For
	10 Andreas Rummelt		For	For
2.	Ratification of appointment by the Board of Directors of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm.	Management	For	For
3.	Approval of a non-binding advisory vote of the 2017 compensation paid to Alexion's named executive officers.	Management	For	For
4.	To request the Board to require an independent Chairman.	Shareholder	For	Against

ALKERMES PLC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

**Security
Ticker Symbol
Record Date**

G01767105
ALKS
23-Mar-2018

**Meeting Type
Meeting Date**

Annual
23-May-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Floyd E. Bloom, M.D.	Management	For	For
1b.	Election of Director: Nancy L. Snyderman, M.D.	Management	For	For
1c.	Election of Director: Nancy Wysenski	Management	For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To hold a non-binding, advisory vote, on the frequency of future advisory votes on the compensation paid to the Company's named executive officers.	Management	1 Year	For
4.	To ratify, on a non-binding, advisory basis, the appointment of PricewaterhouseCoopers LLP as the independent auditor and accounting firm of the Company and to authorize, in a binding vote, the Audit and Risk Committee of the Board of Directors to set the independent auditor and accounting firm's remuneration.	Management	For	For
5.	To approve the Alkermes plc 2018 Stock Option and Incentive plan.	Management	For	For

ALLIQUA BIOMEDICAL, INC.

Security	019621200	Meeting Type	Special
Ticker Symbol	ALQA	Meeting Date	13-Sep-2017
Record Date	26-Jul-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To ratify the filing and effectiveness of the certificate of amendment to our amended and restated certificate of incorporation filed with the secretary of state of the state of delaware on may 6, 2016 and the increase in the number of shares of authorized common stock effected thereby.	Management	For	For
2.	To approve the proposal to authorize the company s board of directors, in its discretion but prior to the annual meeting of the company s stockholders in 2018, to amend the company s certificate of incorporation to effect a reverse stock split of the company s common stock, at a ratio in the range of ...(due to space limits, see proxy statement for full proposal).	Management	For	For
3.	To approve an adjournment of the special meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of any of the foregoing proposals.	Management	For	For

ALLIQUA BIOMEDICAL, INC.

Security	019621309	Meeting Type	Special
Ticker Symbol	ALQA	Meeting Date	27-Apr-2018
Record Date	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	A proposal to approve the Asset Purchase Agreement, the Asset Sale Transaction and the other transactions contemplated by the Asset Purchase Agreement (the Asset Sale Proposal).	Management	For	For
2.	A proposal to approve, on an advisory, non-binding basis, certain compensation that has, will or may be paid or become payable to the Company s named executive officers in connection with the asset sale (the Advisory Proposal).	Management	For	For
3.	A proposal to adjourn or postpone the Special Meeting of stockholders, if necessary or appropriate, for the purpose of soliciting additional votes for the approval of the Asset Sale Proposal (the Adjournment Proposal).	Management	For	For

ALLIQUA BIOMEDICAL, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	019621309	Meeting Type	Annual
Ticker Symbol	ALQA	Meeting Date	26-Jun-2018
Record Date	03-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 David Johnson		For	For
	2 Joseph Leone		For	For
	3 Gary Restani		For	For
	4 Jeffrey Sklar		For	For
	5 Mark Wagner		For	For
2.	Ratification of the appointment of Marcum LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ALNYLAM PHARMACEUTICALS, INC.

Security	02043Q107	Meeting Type	Annual
Ticker Symbol	ALNY	Meeting Date	10-May-2018
Record Date	15-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Dennis A. Ausiello, M.D.	Management	For	For
1b.	Election of Class II Director: John K. Clarke	Management	For	For
1c.	Election of Class II Director: Marsha H. Fanucci	Management	For	For
1d.	Election of Class II Director: David E.I. Pyott	Management	For	For
2.	To approve the 2018 Stock Incentive Plan.	Management	For	For
3.	To approve, in a non-binding advisory vote, the compensation of Alnylam's named executive officers.	Management	For	For
4.	To ratify the appointment of PricewaterhouseCoopers LLP, an independent registered public accounting firm, as Alnylam's independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

AMARIN CORPORATION PLC

Security	023111206	Meeting Type	Annual
Ticker Symbol	AMRN	Meeting Date	14-May-2018
Record Date	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To re-elect Mr. John F. Thero as a director.	Management	For	For
2.	To re-elect Mr. Patrick J. O. Sullivan as a director.	Management	For	For
3.	To hold an advisory (non-binding) vote to approve the compensation of the Company's named executive officers as described in full in the accompanying Proxy Statement.	Management	For	For
4.	To appoint Ernst & Young LLP as auditors of the Company to hold office until the conclusion of the next general meeting at which accounts are laid before the Company and to authorize the Audit Committee of the Board of Directors of the Company to fix the auditors remuneration as described in the accompanying Proxy Statement.	Management	For	For

AMGEN INC.

Security	031162100	Meeting Type	Annual
Ticker Symbol	AMGN	Meeting Date	22-May-2018
Record Date	23-Mar-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Dr. Wanda M. Austin	Management	For	For
1b.	Election of Director: Mr. Robert A. Bradway	Management	For	For
1c.	Election of Director: Dr. Brian J. Druker	Management	For	For
1d.	Election of Director: Mr. Robert A. Eckert	Management	For	For
1e.	Election of Director: Mr. Greg C. Garland	Management	For	For
1f.	Election of Director: Mr. Fred Hassan	Management	For	For
1g.	Election of Director: Dr. Rebecca M. Henderson	Management	For	For
1h.	Election of Director: Mr. Frank C. Herringer	Management	For	For
1i.	Election of Director: Mr. Charles M. Holley, Jr.	Management	For	For
1j.	Election of Director: Dr. Tyler Jacks	Management	For	For
1k.	Election of Director: Ms. Ellen J. Kullman	Management	For	For
1l.	Election of Director: Dr. Ronald D. Sugar	Management	For	For
1m.	Election of Director: Dr. R. Sanders Williams	Management	For	For
2.	Advisory vote to approve our executive compensation.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accountants for the fiscal year ending December 31, 2018.	Management	For	For
4.	Stockholder proposal for an annual report on the extent to which risks related to public concern over drug pricing strategies are integrated into our executive incentive compensation.	Shareholder	Against	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

AMICUS THERAPEUTICS, INC.

Security	03152W109	Meeting Type	Annual
Ticker Symbol	FOLD	Meeting Date	07-Jun-2018
Record Date	16-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Donald J. Hayden, Jr.		For	For
	2 Craig Wheeler		For	For
2.	Proposal to approve an amendment to our Restated Certificate of Incorporation to increase the number of shares of common stock, par value \$0.01 per share, that we are authorized to issue from 250,000,000 to 500,000,000	Management	For	For
3.	Approval of the Amended and Restated 2007 Equity Incentive Plan to add 5,000,000 shares to the equity pool	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018	Management	For	For
5.	Approval, on an advisory basis, the Company's executive compensation	Management	For	For

AMPHIVENA THERAPEUTICS, INC

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	20-Dec-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Amended and Restated Certificate of Incorporation	Management	For	For
2.	Approval of Bridge Loan and Waiver of Right of First Offer	Management	For	For
3.	Omnibus Resolutions	Management	For	For

ARCA BIOPHARMA, INC.

Security	00211Y407	Meeting Type	Annual
Ticker Symbol	ABIO	Meeting Date	31-May-2018
Record Date	02-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	Raymond L. Woosley	For	For
2	Daniel J. Mitchell	For	For
2.	To ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For

ARDELYX, INC

Security	039697107	Meeting Type	Annual
Ticker Symbol	ARDX	Meeting Date	13-Jun-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
1	William Bertrand, Jr.		For	For
2	Annalisa Jenkins		For	For
3	Jan M. Lundberg, Ph.D.		For	For
2.	To ratify the selection, by the Audit Committee of our Board of Directors, of Ernst & Young, LLP as the independent registered public accounting firm of the Company for the fiscal year ended December 31, 2018.	Management	For	For

ARENA PHARMACEUTICALS, INC.

Security	040047607	Meeting Type	Annual
Ticker Symbol	ARNA	Meeting Date	13-Jun-2018
Record Date	24-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jayson Dallas, M.D.		For	For
	2 Oliver Fetzer, Ph.D.		For	For
	3 Jennifer Jarrett		For	For
	4 Amit D. Munshi		For	For
	5 Garry A. Neil, M.D.		For	For
	6 Tina S. Nova, Ph.D.		For	For
	7 Randall E. Woods		For	For
2.	To approve, on an advisory basis, the compensation of our named executive officers, as disclosed in the proxy statement accompanying this notice.	Management	For	For
3.	To approve the amendment and restatement of the Arena Pharmaceuticals, Inc., 2017 Long-Term Incentive Plan to, among other things, increase the number of shares authorized for issuance under the 2017 Long-Term Incentive Plan.	Management	For	For
4.	To ratify the appointment of KPMG LLP, an independent registered public accounting firm, as our independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Special
Ticker Symbol	ARGX	Meeting Date	07-Nov-2017
Record Date	10-Oct-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment of the remuneration policy	Management	For	For
2.	authorization of the board of directors to issue shares in the share capital of the company up to a maximum of 20% of the outstanding capital at the date of the general meeting, for a period of 18 months from the general meeting, in addition to the authorization to issue shares pursuant to the exercise of options	Management	For	For
3.	Authorization of the board of directors to, insofar necessary, limit or exclude pre-emptive rights regarding an issuance of new shares for a period of 18 months from the general meeting	Management	For	For

ARGENX SE

Security	04016X101	Meeting Type	Annual
Ticker Symbol	ARGX	Meeting Date	08-May-2018
Record Date	10-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
4b.	Adoption of the 2017 annual accounts	Management	For	For
4d.	Allocation of losses of the Company in the financial year 2017 to the retained earnings of the Company	Management	For	For
4e.	Proposal to release the members of the board of directors ...(due to space limits, see proxy material for full proposal).	Management	For	For
5a.	Appointment of James Michael Daly as non-executive director to the board of directors of the Company	Management	For	For
5b.	Re-appointment of Tim Van Hauwermeiren as executive director to the board of directors of the Company	Management	For	For
5c.	Re-appointment of David L. Lacey as non-executive director to the board of directors of the Company	Management	For	For
5d.	Re-appointment of Peter K.M. Verhaeghe as non-executive director to the board of directors of the Company	Management	For	For
5e.	Re-appointment of Werner Lanthaler as non-executive director to the board of directors of the Company	Management	For	For
6.	Authorization of the board of directors to grant options ...(due to space limits, see proxy material for full proposal).	Management	For	For
7.	Authorization of the board of directors to issue shares in the ...(due to space limits, see proxy material for full proposal).	Management	For	For
8.	Authorization of the board of directors to limit or exclude ...(due to space limits, see proxy material for full proposal).	Management	For	For
9.	Appointment of Deloitte Accountants B.V. for the 2018 financial year	Management	For	For

ASCENDIS PHARMA A S

Security	04351P101	Meeting Type	Annual
Ticker Symbol	ASND	Meeting Date	29-May-2018
Record Date	19-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Chairman of the Meeting	Management	For	For
2.	Report on the Company s Activities during the Past Year	Management	For	For
3.	Presentation of Audited Annual Report with Auditor s Statement for Approval and Discharge of the Board of Directors and Management	Management	For	For
4.	Resolution on Application of Profits or Covering of Losses as per the Adopted Annual Report	Management	For	For
5a.	Election of Board Member: Albert Cha (Class II)	Management	For	For
5b.	Election of Board Member: Birgitte Volck (Class II)	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

5c.	Election of Board Member: Martin Olin (Class II)	Management	For	For
6.	Election of State-authorized Public Auditor	Management	For	For
7.	Any proposals from the Board of Directors and/or Shareholders: The Board of Directors proposes to renew the authorisation to the Board of Directors to issue warrants. Please refer to the Notice for additional information.	Management	For	For

AURIS MEDICAL HOLDING AG

Security	H03579101	Meeting Type	Annual
Ticker Symbol	EARS	Meeting Date	12-Mar-2018
Record Date	09-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the merger between Auris Medical Holding AG (as transferring entity) and Auris Medical NewCo Holding AG (as surviving entity) according to the terms and conditions set forth by the merger agreement dated 9 February 2018 and based on the interim balance sheet of Auris Medical Holding AG as of 30 September 2017. German Version: Genehmigung der Fusion zwischen der Auris Medical Holding AG (als ubertragende Gesellschaft) und der Auris ... (due to space limits, see proxy statement for full proposal).	Management	For	For
2.	Discharge of liability for the members of the Board of Directors and the Persons entrusted with the Company's Management. German Version: Entlastung der Mitglieder des Verwaltungsrats und der mit der Geschäftsführung der Gesellschaft betrauten Personen.	Management	For	For
3.1	Approval of the Compensation of the Board of Directors. German Version: Genehmigung der Vergütung des Verwaltungsrats.	Management	For	For
3.2	Approval of the Compensation of the members of the Executive Management Committee for the 2019 financial year. German Version: Genehmigung der Vergütung der Geschäftsleitung für das Geschäftsjahr 2019.	Management	For	For
4.1	Re-election of Thomas Meyer as member and as Chairman of the Board of Directors. German Version: Wiederwahl von Thomas Meyer als Mitglied und als Präsident des Verwaltungsrats.	Management	For	For
4.2	Re-election of Armando Anido as member of the Board of Directors. German Version: Wiederwahl von Armando Anido als Mitglied des Verwaltungsrats.	Management	For	For
4.3	Re-election of Mats Peter Blom as member of the Board of Directors. German Version: Wiederwahl von Mats Peter Blom als Mitglied des Verwaltungsrats.	Management	For	For
4.4	Re-election of Calvin W. Roberts as member of the Board of Directors. German Version: Wiederwahl von Calvin W. Roberts als Mitglied des Verwaltungsrats.	Management	For	For
4.5	Election of Alain Munoz as member of the Board of Directors. German Version: Wahl von Alain Munoz als Mitglied des Verwaltungsrats.	Management	For	For
5.1	Re-election of Armando Anido as member of the Compensation Committee. German Version: Wiederwahl von Armando Anido als Mitglied des Vergütungsausschusses.	Management	For	For
5.2	Election of Alain Munoz as member of the Compensation Committee. German Version: Wahl von Alain Munoz als Mitglied des Vergütungsausschusses.	Management	For	For
6.	Re-election of Deloitte AG as Auditors. German Version: Wiederwahl von Deloitte AG als Revisionsstelle.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

7.	Re-election of the Independent Proxy. German Version: Wiederwahl des unabhängigen Stimmrechtsvertreters.	Management	For	For
8.	General instruction on new proposals of the Board of Directors. German Version: Allgemeine Weisungen zu nicht angekündigten Anträgen / Verhandlungsgegenständen.	Management	For	For

AVADEL PHARMACEUTICALS PLC

Security	05337M104	Meeting Type	Annual
Ticker Symbol	AVDL	Meeting Date	18-Jul-2018
Record Date	15-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Craig R. Stapleton	Management	For	For
1b.	Election of Director: Michael S. Anderson	Management	For	For
1c.	Election of Director: Peter Thornton	Management	For	For
1d.	Election of Director: Geoffrey M. Glass	Management	For	For
1e.	Election of Director: Linda S. Palczuk	Management	For	For
2.	To ratify, in a non-binding vote, the appointment of Deloitte & Touche LLP as the Company's independent registered public auditor and accounting firm for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the Audit Committee of the Board to set the independent registered public auditor and accounting firm remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of the named executive officers of the Company.	Management	For	For
4.	To authorize the price range at which the Company can re-allot ordinary shares that it holds as treasury shares under Irish law.	Management	For	For

BEIGENE LTD

Security	07725L102	Meeting Type	Annual
Ticker Symbol	BGNE	Meeting Date	06-Jun-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	THAT Donald W. Glazer be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general ... (due to space limits, see proxy material for full proposal).	Management	For	For
2.	THAT Michael Goller be and is hereby re-elected to serve as a ... (due to space limits, see proxy material for full proposal).	Management	For	For
3.	THAT Thomas Malley be and is hereby re-elected to serve as a Class II director of the Company until the 2021 annual general meeting of the shareholders of the Company and until his successor is duly elected and qualified, subject to his earlier resignation or removal.	Management	For	For
4.	THAT the BeiGene, Ltd. 2018 Employee Share Purchase Plan be and is hereby approved and adopted.	Management	For	For
5.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	THAT the appointment of Ernst & Young Hua Ming LLP as the Company's independent registered public accounting firm for the ...(due to space limits, see proxy material for full proposal).			
6.	THAT, on a non-binding, advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement for the Meeting, be and is hereby approved.	Management	For	For
7.	THAT, on a non-binding, advisory basis, future advisory votes on the compensation of the Company's named executive officers will be held at the frequency hereby approved.	Management	1 Year	For

BELLICUM PHARMACEUTICALS INC

Security	079481107	Meeting Type	Annual
Ticker Symbol	BLCM	Meeting Date	14-Jun-2018
Record Date	17-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Frank B. McGuyer		For	For
	2 Jon P. Stonehouse		For	For
	3 Stephen R. Davis		For	For
2.	Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	27-Sep-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Director	Management	For	For
2.	General Authorizing Resolution	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	24-Apr-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Amendment and Restatement of Restated Certificate of Incorporation	Management	For	For
2.	Series B Preferred Stock Financing	Management	For	For
3.	Waiver of Preemptive Rights	Management	For	For
4.	Notice of Interested Party Transactions	Management	For	For
5.	Amendment of 2013 Stock and Option Grant Plan	Management	For	For
6.	General Authorizing Resolution	Management	For	For

BIOCLIN THERAPEUTICS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	21-May-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Election of Director	Management	For	For
2.	General Authorizing Resolution	Management	For	For

BIOGEN INC.

Security	09062X103	Meeting Type	Annual
Ticker Symbol	BIIB	Meeting Date	12-Jun-2018
Record Date	17-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Alexander J. Denner	Management	For	For
1b.	Election of Director: Caroline D. Dorsa	Management	For	For
1c.	Election of Director: Nancy L. Leaming	Management	For	For
1d.	Election of Director: Richard C. Mulligan	Management	For	For
1e.	Election of Director: Robert W. Pangia	Management	For	For
1f.	Election of Director: Stelios Papadopoulos	Management	For	For
1g.	Election of Director: Brian S. Posner	Management	For	For
1h.	Election of Director: Eric K. Rowinsky	Management	For	For
1i.	Election of Director: Lynn Schenk	Management	For	For
1j.	Election of Director: Stephen A. Sherwin	Management	For	For
1k.	Election of Director: Michel Vounatsos	Management	For	For
2.	To ratify the selection of PricewaterhouseCoopers LLP as Biogen Inc. s independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Say on Pay - To approve an advisory vote on executive compensation.	Management	For	For
4.	Stockholder proposal requesting certain proxy access bylaw amendments.	Shareholder	Against	For
5.	Stockholder proposal requesting a report on the extent to which risks related to public concern over drug pricing strategies are integrated into incentive compensation arrangements.	Shareholder	Against	For

BIOHAVEN PHARMACEUTICAL HLDG CO LTD

Security	G11196105	Meeting Type	Annual
Ticker Symbol	BHVN	Meeting Date	01-May-2018
Record Date	26-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Dr. Eric I. Aguiar	Management	For	For
1B.	Election of Director: Dr. Albert Cha	Management	For	For
1C.	Election of Director: Ms. Julia P. Gregory	Management	For	For
2.	Ratification of appointment of PricewaterhouseCoopers LLP as independent auditors for fiscal year 2018.	Management	For	For

BIOMARIN PHARMACEUTICAL INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security
Ticker Symbol
Record Date

09061G101
BMRN
09-Apr-2018

Meeting Type
Meeting Date

Annual
05-Jun-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jean-Jacques Bienaime		For	For
	2 Willard Dere		For	For
	3 Michael Grey		For	For
	4 Elaine J. Heron		For	For
	5 Robert J. Hombach		For	For
	6 V. Bryan Lawlis		For	For
	7 Alan J. Lewis		For	For
	8 Richard A. Meier		For	For
	9 David E.I. Pyott		For	For
	10 Dennis J. Slamon		For	For
2.	To ratify the selection of KPMG LLP as the independent registered public accounting firm for BioMarin for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.	Management	For	For

BLUEBIRD BIO, INC.

Security	09609G100	Meeting Type	Annual
Ticker Symbol	BLUE	Meeting Date	20-Jun-2018
Record Date	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: John O. Agwunobi, M.D.	Management	For	For
1b.	Election of Class II Director: Mary Lynne Hedley, Ph.D	Management	For	For
1c.	Election of Class II Director: Daniel S. Lynch	Management	For	For
2.	To hold a non-binding advisory vote on the compensation paid to the Company's named executive officers.	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

BLUEPRINT MEDICINES CORPORATION

Security	09627Y109	Meeting Type	Annual
Ticker Symbol	BPMC	Meeting Date	20-Jun-2018
Record Date	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Daniel S. Lynch		For	For
	2 George D. Demetri, M.D.		For	For
	3 Lynn Seely, M.D.		For	For
2.	To approve an advisory vote on named executive officer compensation.	Management	For	For
3.	To hold an advisory vote on the frequency of future advisory votes on named executive officer compensation.	Management	1 Year	For
4.	Ratification of the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ended December 31, 2018.	Management	For	For

CELGENE CORPORATION

Security
Ticker Symbol
Record Date

151020104
CELG
19-Apr-2018

Meeting Type
Meeting Date

Annual
13-Jun-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Mark J. Alles		For	For
	2 R W Barker, D.Phil, OBE		For	For
	3 Hans E. Bishop		For	For
	4 Michael W. Bonney		For	For
	5 Michael D. Casey		For	For
	6 Carrie S. Cox		For	For
	7 Michael A. Friedman, MD		For	For
	8 Julia A. Haller, M.D.		For	For
	9 P. A. Hemingway Hall		For	For
	10 James J. Loughlin		For	For
	11 Ernest Mario, Ph.D.		For	For
	12 John H. Weiland		For	For
2.	Ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approval, by non-binding vote, of executive compensation of the Company's named executive officers.	Management	For	For
4.	Advisory vote on stockholder proposal to request the Company's Board of Directors to amend the Company's proxy access by-law provision to eliminate the limit on the number of stockholders that can aggregate their shares to achieve the holding requirement for nomination of directors, described in more detail in the proxy statement.	Shareholder	Against	For
5.	Advisory vote on stockholder proposal to request the Company's Board of Directors to adopt a policy and amend the Company's governing documents to require that the Chairman of the Board be an independent member, described in more detail in the proxy statement.	Shareholder	For	Against

CELLECTIS S.A.

Security	15117K103	Meeting Type	Annual
Ticker Symbol	CLLS	Meeting Date	26-Jun-2018
Record Date	11-Jun-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of the financial statements for the financial year ended December 31, 2017	Management	For	For
2.	Approval of the consolidated financial statements for the financial year ended December 31, 2017	Management	For	For
3.	Allocation of income for the financial year ended December 31, 2017	Management	For	For
4.	Approval of the agreements referred to in articles L. 225-38 and the following sections of the French commercial code	Management	For	For
5.	Setting the amount of the attendance fees to be granted to the non-executive directors	Management	For	For
6.	Renewal of the term of office of director of Mr. Andre Choulika	Management	For	For
7.	Renewal of the term of office of director of Mr. David Sourdiv	Management	For	For
8.	Renewal of the term of office of director of Mr. Alain-Paul Godard, independent director according to the rules of the U.S. Securities Exchange Act of 1934 (the Exchange Act) and Nasdaq Stock Market	Management	For	For
9.	Renewal of the term of office of J.M.H. Conseil, as Company's Statutory Auditors	Management	For	For
10.	Renewal of the term of office of Ernst & Young et Autres, as Company's Statutory Auditors	Management	For	For
11.	Approval of 2017 Stock Option Plan and payment for the stock options or stock purchase plan adopted by the Board of Directors on October 11, 2017	Management	For	For
12.	Authorization to be given to the Board of Directors to buy back Company shares	Management	For	For
13.	Authorization to be given to the Board of Directors for the purpose of reducing the share capital through the cancellation of shares in the context of the authorization to buy back its own shares	Management	For	For
14.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by issuing ordinary shares and/or any securities, with a waiver of the preferential subscription rights of the shareholders, in favor of a category of persons meeting specified characteristics	Management	For	For
15.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares or of any securities with a waiver of the preferential subscription rights of the shareholders, in favor of a category of persons ensuring the underwriting of the Company's equity securities that may arise as part of an equity line financing or bond financing	Management	For	For
16.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

immediately or in the future by issuing ordinary shares or any securities, while maintaining the preferential subscription rights of shareholders

17.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares and/or any securities, with waiver of the preferential subscription rights of the shareholders, through a public offering	Management	For	For
18.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital through the issuance of ordinary shares and/or of any securities, with waiver of the preferential subscription rights of the shareholders, through an offer to qualified investors or a restricted circle of investors within the meaning of paragraph II of article L. 411-2 of the French monetary and financial code	Management	For	For
19.	Delegation granted to the Board of Directors to increase the number of securities to be issued in case of share capital increase with or without preferential subscription rights	Management	For	For
20.	Overall limitations to the amount of issuances made under the 14th resolution, the 15th resolution, the 16th resolution, the 17th resolution, the 18th resolution, and the 19th resolution above	Management	For	For
21.	Delegation of authority to be granted to the Board of Directors for the purpose of increasing the share capital by incorporation of premiums, reserves, profits or others	Management	For	For
22.	Authorization to be given to the Board of Directors to grant options to subscribe or purchase Company's shares	Management	For	For
23.	Authorization be given to the Board of Directors for the allocation of free shares existing and/or to be issued in the future	Management	For	For
24.	Delegation of authority to be granted to the Board of Directors to issue warrants giving the right to subscribe ordinary shares of the Company - Cancellation of the preferential right of subscription to the benefit of a category of persons meeting specific characteristics	Management	For	For
25.	Delegation of authority to be granted to the Board of Directors for the purpose of issuing warrants to subscribe to and/or acquire redeemable shares (BSAAR) or share subscription warrants - with a waiver of the preferential subscription rights in favor of the following category of beneficiaries: employees and corporate officers of the Company and its subsidiaries	Management	For	For
26.	Authorization for the Board of Directors to freely allocate preferred shares of the Company to the employees and and/or the executive officers of the Company and its subsidiaries entailing the waiver by the shareholders of their preferential subscription rights	Management	For	For
27.	Overall limitations to the amount of issues made under the 22nd resolution, the 23rd resolution, the 24th resolution, the 25th resolution and the 26th resolution above	Management	For	For
28.	Removal of the obligation to submit certain decisions to the Board of Directors' approval, as listed in Article 14.1.1. Section 4 of the bylaws	Management	For	For
29.	Delegation to be granted to the Board of Directors for the purpose of an increase in the share capital whose subscription would be reserved to members of a company savings plan established pursuant to articles L. 3332-1 and following of the French labor code	Management	For	N/A

CIDARA THERAPEUTICS, INC.

Security	171757107	Meeting Type	Annual
Ticker Symbol	CDTX	Meeting Date	13-Jun-2018
Record Date	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Timothy Franson		For	For
	2 Chrysa Mineo		For	For
2.	Ratification of the appointment of the company's independent registered public accounting firm for its fiscal year ending December 31, 2018	Management	For	For

CLOVIS ONCOLOGY, INC.

Security	189464100	Meeting Type	Annual
Ticker Symbol	CLVS	Meeting Date	07-Jun-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Patrick J. Mahaffy		For	For
	2 M. James Barrett, Ph.D.		For	For
	3 Thorlef Spickschen		For	For
2.	Approval and ratification of our Non-Employee Director Compensation Policy.	Management	For	For
3.	Approval of an advisory proposal on compensation of the Company's named executive officers, as disclosed in the attached proxy statement.	Management	For	For
4.	Approval of an advisory proposal on the preferred frequency of the stockholder vote on the compensation of the Company's named executive officers.	Management	1 Year	For
5.	Ratification of the appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2018.	Management	For	For

CRISPR THERAPEUTICS AG

Security Ticker Symbol Record Date	H17182108 CRSP 02-Apr-2018	Meeting Type Meeting Date	Annual 30-May-2018
---	----------------------------------	--------------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1.	The approval of the annual report, the consolidated financial statements and the statutory financial statements of the Company for the year ended December 31, 2017.	Management	For	For
2.	The approval of the appropriation of financial results.	Management	For	For
3.	The discharge of the members of the Board of Directors and Executive Committee.	Management	For	For
4a.	Re-election of the member to the Board of Director: Rodger Novak, M.D. (as member and Chairman)	Management	For	For
4b.	Election of the member to the Board of Director: Samarth Kulkarni, Ph.D.	Management	For	For
4c.	Re-election of the member to the Board of Director: Bradley Bolzon, Ph.D.	Management	For	For
4d.	Re-election of the member to the Board of Director: Ali Behbahani, M.D.	Management	For	For
4e.	Re-election of the member to the Board of Director: Pablo Cagnoni, M.D.	Management	For	For
4f.	Re-election of the member to the Board of Director: Kurt von Emster	Management	For	For
4g.	Re-election of the member to the Board of Director: Simeon J. George, M.D.	Management	For	For
4h.	Re-election of the member to the Board of Director: Thomas Woiwode, Ph.D.	Management	For	For
5a.	Re-election of the member of the Compensation Committee: Thomas Woiwode, Ph.D.	Management	For	For
5b.	Re-election of the member of the Compensation Committee: Pablo Cagnoni, M.D.	Management	For	For
5c.	Re-election of the member of the Compensation Committee: Simeon J. George, M.D.	Management	For	For
6a.	Binding vote on total non-performance-related compensation for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
6b.	Binding vote on equity for members of the Board of Directors from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
6c.	Binding vote on total non-performance-related compensation for members of the Executive Committee from July 1, 2018 to June 30, 2019.	Management	For	For
6d.	Binding vote on total variable compensation for members of the Executive Committee for the current year ending December 31, 2018.	Management	For	For
6e.	Binding vote on equity for members of the Executive Committee from the 2018 Annual General Meeting to the 2019 annual general meeting of shareholders.	Management	For	For
7.	The approval of an increase in the Conditional Share Capital for Employee Benefit Plans.	Management	For	For
8.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	The approval of the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan.			
9.	The approval of increasing the maximum number of authorized share capital and extending the date by which the Board of Directors may increase authorized share capital.	Management	For	For
10.	The re-election of the independent voting rights representative.	Management	For	For
11.	The re-election of the auditors.	Management	For	For

CYMABAY THERAPEUTICS INC

Security	23257D103	Meeting Type	Annual
Ticker Symbol	CBAY	Meeting Date	05-Jun-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Sujal A. Shah	For	For
	2	Robert F. Booth, Ph.D.	For	For
	3	Carl Goldfischer, M.D.	For	For
	4	Caroline Loewy	For	For
	5	Evan A. Stein, M.D. PhD	For	For
	6	Paul F. Truex	For	For
	7	Kurt von Emster	For	For
	8	Robert J. Weiland	For	For
	9	Robert J. Wills, Ph.D.	For	For
2.	To approve the CymaBay Therapeutics, Inc. 2013 Equity Incentive Plan, as amended and restated, to, among other things, increase the aggregate number of shares of the company's common stock authorized for issuance under the plan by 1,500,000 shares.	Management	For	For
3.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as the independent registered public accounting firm of CymaBay Therapeutics, Inc. for its fiscal year ending December 31, 2018.	Management	For	For

CYTOKINETICS, INCORPORATED

Security	23282W605	Meeting Type	Annual
Ticker Symbol	CYTK	Meeting Date	16-May-2018
Record Date	03-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Robert I. Blum	For	For
	2	Robert M. Califf M.D.	For	For
	3	Sandford D. Smith	For	For
2.	Ratification of selection of Ernst & Young LLP as the independent registered public accounting firm of Cytokinetics, Incorporated for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approval, on an advisory basis, of the compensation of the named executive officers.	Management	For	For

CYTOMX THERAPEUTICS, INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	23284F105	Meeting Type	Annual
Ticker Symbol	CTMX	Meeting Date	13-Jun-2018
Record Date	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Charles S. Fuchs	Management	For	For
1b.	Election of Director: Hoyoung Huh	Management	For	For
2.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.	Management	For	For

DERMIRA, INC.

Security	24983L104	Meeting Type	Annual
Ticker Symbol	DERM	Meeting Date	12-Jun-2018
Record Date	16-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Matthew K. Fust		For	For
	2 William R. Ringo		For	For
	3 Kathleen Sebelius		For	For
2.	Vote, on a non-binding advisory basis, on the compensation paid by us to our named executive officers for the year ended December 31, 2017.	Management	For	For
3.	Ratification of the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2018.	Management	For	For
4.	Such other business as may properly come before the meeting or any adjournment thereof.	Management	Abstain	Against

DYNAVAX TECHNOLOGIES CORPORATION

Security	268158201	Meeting Type	Special
Ticker Symbol	DVAX	Meeting Date	31-Jul-2017
Record Date	30-Jun-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve an amendment to the company's sixth amended and restated certificate of incorporation, as amended, to increase the authorized number of shares of common stock from 69,500,000 to 139,000,000.	Management	For	For
2.	To authorize an adjournment of the meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of the proposal 1.	Management	For	For

EDITAS MEDICINE INC

Security	28106W103	Meeting Type	Annual
Ticker Symbol	EDIT	Meeting Date	15-Jun-2018
Record Date	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

1	Andrew Hirsch		For	For
2	Boris Nikolic, M.D.		For	For
2.	Ratification of the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

EIGER BIOPHARMACEUTICALS, INC

Security	28249U105	Meeting Type	Annual
Ticker Symbol	EIGR	Meeting Date	12-Jun-2018
Record Date	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Thomas J. Dietz, Ph.D		For	For
	2 Eldon Mayer		For	For
2.	To ratify the selection by the Audit Committee of our Board of Directors of KPMG LLP as our independent registered public accounting firm for our fiscal year ending December 31, 2018.	Management	For	For

ENDO INTERNATIONAL PLC

Security	G30401106	Meeting Type	Annual
Ticker Symbol	ENDP	Meeting Date	07-Jun-2018
Record Date	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Roger H. Kimmel	Management	For	For
1b.	Election of Director: Paul V. Campanelli	Management	For	For
1c.	Election of Director: Shane M. Cooke	Management	For	For
1d.	Election of Director: Nancy J. Hutson, Ph.D.	Management	For	For
1e.	Election of Director: Michael Hyatt	Management	For	For
1f.	Election of Director: Sharad S. Mansukani, M.D.	Management	For	For
1g.	Election of Director: William P. Montague	Management	For	For
1h.	Election of Director: Todd B. Sisitsky	Management	For	For
2.	To approve the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018 and to authorize the Board of Directors, acting through the Audit Committee, to determine the independent registered public accounting firm's remuneration.	Management	For	For
3.	To approve, by advisory vote, named executive officer compensation.	Management	For	For
4.	To approve the Endo International plc Amended and Restated 2015 Stock Incentive Plan.	Management	For	For
5.	To renew the Board's existing authority to issue shares under Irish law.	Management	For	For
6.	To renew the Board's existing authority to opt-out of statutory pre-emption rights under Irish law.	Management	For	For

EPIZYME, INC.

Security	29428V104	Meeting Type	Annual
Ticker Symbol	EPZM	Meeting Date	18-May-2018
Record Date	23-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Kevin Conroy		For	For
	2 Carl Goldfischer, M.D.		For	For
	3 Beth Seidenberg, M.D.		For	For
2.	Ratification of the appointment of Ernst & Young LLP as Epizyme's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

ESPERION THERAPEUTICS INC

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	29664W105	Meeting Type	Annual
Ticker Symbol	ESPR	Meeting Date	23-May-2018
Record Date	26-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Jeffrey Berkowitz, J.D.	Management	For	For
1b.	Election of Class II Director: Antonio M. Gotto Jr., M.D., D.Phil.	Management	For	For
1c.	Election of Class II Director: Nicole Vitullo	Management	For	For
2.	To approve the advisory resolution on the compensation of our named executive officers	Management	For	For
3.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018	Management	For	For

EUTHYMICS BIOSCIENCE, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	11-Jul-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Bridge Financing	Management	For	For

EUTHYMICS BIOSCIENCE, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	27-Sep-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Sale and Dissolution	Management	For	For
2.	Dissolution	Management	For	For
3.	General	Management	For	For

EXELIXIS, INC.

Security	30161Q104	Meeting Type	Annual
Ticker Symbol	EXEL	Meeting Date	23-May-2018
Record Date	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director: Charles Cohen, Ph.D.	Management	For	For
1.2	Election of Class I Director: George Poste, DVM, Ph.D., FRS	Management	For	For
1.3	Election of Class I Director: Jack L. Wyszomierski	Management	For	For
2.	To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young LLP as Exelixis independent registered public accounting firm for the fiscal year ending December 28, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of Exelixis named executive officers, as disclosed in the accompanying Proxy Statement.	Management	For	For

FIBROGEN, INC.

Security	31572Q808	Meeting Type	Annual
Ticker Symbol	FGEN	Meeting Date	05-Jun-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class I Director: Thomas B. Neff	Management	For	For
1b.	Election of Class I Director: Jeffrey W. Henderson	Management	For	For
1c.	Election of Class I Director: James A. Schoeneck	Management	For	For
2.	To approve, on an advisory basis, the compensation of FibroGen s named executive officers, as disclosed in the proxy statement.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

3.	To ratify the selection of PricewaterhouseCoopers LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of FibroGen for the year ending December 31, 2018.	Management	For	For
----	--	------------	-----	-----

FOAMIX PHARMACEUTICALS LTD

Security	M46135105	Meeting Type	Special
Ticker Symbol	FOMX	Meeting Date	27-Nov-2017
Record Date	25-Oct-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	(i) Pay mr. domzalski annual compensation of \$440,000 for his services as the chief executive officer of the company, effective as of July 1, 2017, (ii) approve mr. domzalski's cash bonus for the six month period commencing as of July 1, 2017 up to a maximum amount of \$132,000, subject to ...(due to space limits, see proxy statement for full proposal).	Management	For	For
1A.	Do you have a personal interest in the approval of this proposal #1? mark for = yes or against = no.	Management	Against	N/A
2.	Award mr. domzalski 327,720 options and 81,930 rsus under the company's 2015 Israeli share incentive plan and its 2015 U.S. addendum.	Management	For	For
2A.	Do you have a personal interest in the approval of this proposal #2? mark for = yes or against = no.	Management	Against	N/A

FOAMIX PHARMACEUTICALS LTD

Security Ticker Symbol Record Date	M46135105 FOMX 10-Apr-2018	Meeting Type Meeting Date	Annual 08-May-2018
---	----------------------------------	----------------------------------	-----------------------

Item	Proposal	Proposed by	Vote	For/Against Management
1	Appoint Kesselman & Kesselman (a member firm of PricewaterhouseCoopers International Limited, or PwC) an independent registered public accounting firm, as the Company's independent public accountants for the fiscal year ending December 31, 2018, and authorize the Board (or the Audit Committee, if such authority is delegated to it by the Board) to fix the remuneration of such independent public accountants in accordance with the volume and nature of their services.	Management	For	For
2	Ratify the election of Mr. David Domzalski as a director of the Company.	Management	For	For
3	Approve the annual equity incentive awards to the Company's non-executive directors, as set out under Proposal 3 in the Company's proxy statement.	Management	For	For
4a	Approve the equity incentive grants to Mr. Domzalski for 2017, as set out under Proposal 4(a) in the Company's proxy statement.	Management	For	For
4a1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
4b	Approve the terms of Mr. Domzalski's cash bonus and equity compensation for 2018, as set out under Proposal 4(b) of the Company's proxy statement.	Management	For	For
4b1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 4(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
5a	Approve the 2016 equity conversion bonus for Dr. Tamarkin in respect of 2016, as set out under Proposal 5(a) of the Company's proxy statement	Management	For	For
5a1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(a)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
5b	Approve Dr. Tamarkin's cash bonus in respect of the first half of 2017, as set out under Proposal 5(b) of the Company's proxy statement.	Management	For	For
5b1	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 5(b)? If you vote FOR=YES or not at all your vote may not count for the Corresponding Proposal For= Yes, No=Against	Management	Against	N/A
6.	Approve the Company's Amended Compensation Policy, as set out under Proposal 6 of the Company's proxy statement.	Management	For	For
6a	Please confirm you are a controlling shareholder/have a personal interest in the approval of Proposal 6? If you vote FOR=YES or not at all your vote may not count for the	Management	Against	N/A

Corresponding Proposal For= Yes, No=Against

GALAPAGOS N V

Security	36315X101	Meeting Type	Annual
Ticker Symbol	GLPG	Meeting Date	24-Apr-2018
Record Date	20-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
2.	Acknowledgement and approval of the non-consolidated annual accounts of the Company for the financial year ended on 31 December 2017 and approval of the allocation of the annual result as proposed by the board of directors.	Management	For	N/A
5.	Acknowledgement and approval of the remuneration report.	Management	For	N/A
6.	Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 December 2017.	Management	For	N/A
7.1	Re-appointment of Dr. Werner Cautreels as director of the Company.	Management	For	N/A
7.2	Re-appointment of Mr. Howard Rowe as director of the Company.	Management	For	N/A
8.	Remuneration of directors.	Management	For	N/A
9.	Offer of warrants.	Management	For	N/A

GALAPAGOS N V

Security	B44170106	Meeting Type	Annual General Meeting
Ticker Symbol	GLPG NA	Meeting Date	24-Apr-2018
Record Date	10-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
CMMT	Market rules require disclosure of beneficial owner information for all voted-accounts. If an account has multiple beneficial owners, you will need to-provide the breakdown of each beneficial owner name, address and share-position to your client service representative. This information is required-in order for your vote to be lodged	Non-Voting	N/A	N/A
CMMT	Important market processing requirement: a beneficial owner signed power of- attorney (poa) may be required in order to lodge and execute your voting- instructions in this market. Absence of a poa, may cause your instructions to-be rejected. If you have any questions, please contact your client service- representative	Non-Voting	N/A	N/A
1	Acknowledgement and discussion of the annual report of the board of directors- relating to the non-consolidated and consolidated annual accounts of the- company for the financial year ended on 31 december 2017, and of the report-of the statutory auditor relating to the non-consolidated annual accounts of-the company for the financial year ended on 31 december 2017	Non-Voting	N/A	N/A
2	Acknowledgement and approval of the non-consolidated annual accounts of the company for the financial year ended on 31 december 2017 and approval of the allocation of the annual result as proposed by the board of directors	Management	For	For
3	Acknowledgement and discussion of the report of the statutory auditor-relating to the consolidated annual accounts of the company for the financial-year ended on 31 december 2017	Non-Voting	N/A	N/A
4	Acknowledgement and discussion of the consolidated annual accounts of the- company for the financial year ended on 31 december 2017	Non-Voting	N/A	N/A
5	Acknowledgement and approval of the remuneration report	Management	For	For
6	Release from liability to be granted to the directors and the statutory auditor for the performance of their duties in the course of the financial year ended 31 december 2017	Management	For	For
7.I	The shareholders meeting resolves to re- appoint dr. werner cautreels (residing in boston, ma, united states of america) as director of the company, for a period of one year ending immediately after the annual shareholders meeting to be held in 2019	Management	For	For
7.II	The shareholders meeting resolves to re- appoint mr. howard rowe (residing in london, united kingdom) as director of the company, for a period of four years ending immediately after the annual shareholders meeting to be held in 2022 and, upon the proposal of the board of directors and in accordance with the advice of the company s nomination and remuneration committee, to	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

appoint mr. rowe as an independent director as he meets
the independence criteria set forth in article 526ter of the
belgian companies code

8	Remuneration of directors	Management	For	For
9	Offer of warrants	Management	For	For
10	Miscellaneous	Non-Voting	N/A	N/A

GENOMEDX BIOSCIENCES, INC.

Security	N/A	Meeting Type	Special
Ticker Symbol	N/A	Meeting Date	20-Nov-2017
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Authorized Share Structure Amendment Resolution	Management	For	For
2.	Special Rights and Restrictions Resolution	Management	For	For
3.	Class C Preferred Share Issuance Resolution	Management	For	For

GENOMEDX BIOSCIENCES, INC.

Security	N/A	Meeting Type	Special
Ticker Symbol	N/A	Meeting Date	8-Jan-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Special Rights and Restrictions Resolution	Management	For	For

GENOMEDX BIOSCIENCES, INC.

Security	N/A	Meeting Type	Special
Ticker Symbol	N/A	Meeting Date	4-Feb-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Authorized Share Structure Amendment Resolution	Management	For	For
3.	Articles Amendment Resolution	Management	For	For
4.	New Preferred Share Issuance Resolution	Management	For	For

GENOMEDX BIOSCIENCES, INC.

Security	N/A	Meeting Type	Special
Ticker Symbol	N/A	Meeting Date	31-Mar-2018
Record Date	N/A		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Authorized Share Structure Amendment Resolution	Management	For	For
3.	Articles Amendment Resolution	Management	For	For
4.	New Preferred Share Issuance Resolution	Management	For	For

GENOMEDX BIOSCIENCES, INC.

Security	N/A	Meeting Type	Special
Ticker Symbol	N/A	Meeting Date	9-Jul-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Non-shareholders as Proxyholders Resolution	Management	For	For
2.	Domestication Resolution	Management	For	For

GILEAD SCIENCES, INC.

Security	375558103	Meeting Type	Annual
Ticker Symbol	GILD	Meeting Date	09-May-2018
Record Date	16-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: John F. Cogan, Ph.D.	Management	For	For
1b.	Election of Director: Jacqueline K. Barton, Ph.D.	Management	For	For
1c.	Election of Director: Kelly A. Kramer	Management	For	For
1d.	Election of Director: Kevin E. Lofton	Management	For	For
1e.	Election of Director: John C. Martin, Ph.D.	Management	For	For
1f.	Election of Director: John F. Milligan, Ph.D.	Management	For	For
1g.	Election of Director: Richard J. Whitley, M.D.	Management	For	For
1h.	Election of Director: Gayle E. Wilson	Management	For	For
1i.	Election of Director: Per Wold-Olsen	Management	For	For
2.	To ratify the selection of Ernst & Young LLP by the Audit Committee of the Board of Directors as the independent registered public accounting firm of Gilead for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of our Named Executive Officers as presented in the Proxy Statement.	Management	For	For
4.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board adopt a policy that the Chairman of the Board of Directors be an independent director.	Shareholder	Against	For
5.	To vote on a stockholder proposal, if properly presented at the meeting, requesting that the Board take steps to permit stockholder action by written consent.	Shareholder	Against	For

GLAUKOS CORPORATION

Security	377322102	Meeting Type	Annual
Ticker Symbol	GKOS	Meeting Date	31-May-2018
Record Date	05-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Thomas W. Burns		For	For
	2 Gilbert H. Kliman, M.D.		For	For
	3 Marc A. Stapley		For	For
2.	Approval, on an advisory basis, of the compensation of the Company's named executive officers.	Management	For	For
3.	Approval, on an advisory basis, of the frequency of future advisory votes on executive compensation.	Management	1 Year	For
4.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2018.	Management	For	For

GLOBAL BLOOD THERAPEUTICS, INC.

Security	37890U108	Meeting Type	Annual
Ticker Symbol	GBT	Meeting Date	20-Jun-2018
Record Date	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Scott W. Morrison		For	For
	2 Deval L. Patrick		For	For
	3 Mark L. Perry		For	For
2.	Approval, on a non-binding, advisory basis, of the compensation of the Company's named executive officers as disclosed in the proxy statement.	Management	For	For
3.	Recommendation, on a non-binding, advisory basis, of the preferred frequency of future advisory votes on the compensation of the Company's named executive officers.	Management	1 Year	For
4.	Ratification of the appointment of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For
5.	Transaction of such other business as may properly come before the meeting or any adjournment or postponement thereof.	Management	For	For

GW PHARMACEUTICALS PLC

Security	36197T103	Meeting Type	Annual
Ticker Symbol	GWPH	Meeting Date	14-Mar-2018
Record Date	05-Feb-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
O1	TO RECEIVE, CONSIDER AND ADOPT THE DIRECTORS' AND AUDITORS' REPORTS AND STATEMENT OF ACCOUNTS FOR THE YEAR ENDED 30 SEPTEMBER 2017 AND NOTE THAT THE DIRECTORS DO NOT RECOMMEND PAYMENT OF A DIVIDEND	Management	For	N/A
O2	TO APPROVE THE DIRECTORS' REMUNERATION REPORT	Management	For	N/A
O3	TO APPROVE THE DIRECTORS' REMUNERATION POLICY	Management	For	N/A
O4	TO RE-ELECT JUSTIN GOVER AS A DIRECTOR	Management	For	N/A
O5	TO ELECT CATHERINE MACKEY AS A DIRECTOR	Management	For	N/A
O6	TO ELECT ALICIA SECOR AS A DIRECTOR	Management	For	N/A
O7	TO ELECT WILLIAM WALDEGRAVE AS A DIRECTOR	Management	For	N/A
O8	TO RE-APPOINT DELOITTE LLP AS AUDITOR	Management	For	N/A
O9	To authorise the Directors to determine the Auditor's remuneration	Management	For	N/A

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

O10	To authorise the Directors to allot shares pursuant to Section 551 of the Companies Act 2006 (the 2006 Act)	Management	For	N/A
S11	Subject to the passing of Resolution 10, to authorise the ... (due to space limits, see proxy material for full proposal).	Management	For	N/A
S12	To adopt new articles of association of the Company in ... (due to space limits, see proxy material for full proposal).	Management	For	N/A

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

IDEXX LABORATORIES, INC.

Security	45168D104	Meeting Type	Annual
Ticker Symbol	IDXX	Meeting Date	09-May-2018
Record Date	16-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Bruce L. Claflin	Management	For	For
1b.	Election of Director: Daniel M. Junius	Management	For	For
2.	Ratification of Appointment of Independent Registered Public Accounting Firm. To ratify the selection of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the current fiscal year.	Management	For	For
3.	Approval of the Adoption of the IDEXX Laboratories, Inc. 2018 Incentive Plan. To approve the Company's 2018 Stock Incentive Plan.	Management	For	For
4.	Advisory Vote on Executive Compensation. To approve a nonbinding advisory resolution on the Company's executive compensation.	Management	For	For

ILLUMINA, INC.

Security	452327109	Meeting Type	Annual
Ticker Symbol	ILMN	Meeting Date	23-May-2018
Record Date	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Jay T. Flatley	Management	For	For
1b.	Election of Director: John W. Thompson	Management	For	For
1c.	Election of Director: Gary S. Guthart, Ph.D.	Management	For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 30, 2018.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement.	Management	For	For
4.	To approve, on an advisory basis, a stockholder proposal to elect each director annually.	Shareholder	Against	For

ILLUMINOSS MEDICAL, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	14-Nov-2017
Record Date	N/A		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Sixth Amended and Restated Certificate of Incorporation	Management	For	For
2.	Convertible Note Financing	Management	For	For
3.	Amendment of March 2017 Notes and Warrants	Management	For	For
4.	Anti-Dilution	Management	For	For
5.	General Resolutions	Management	For	For

INCYTE CORPORATION

Security	45337C102	Meeting Type	Annual
Ticker Symbol	INCY	Meeting Date	01-May-2018
Record Date	05-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Julian C. Baker	Management	For	For
1.2	Election of Director: Jean-Jacques Bienaime	Management	For	For
1.3	Election of Director: Paul A. Brooke	Management	For	For
1.4	Election of Director: Paul J. Clancy	Management	For	For
1.5	Election of Director: Wendy L. Dixon	Management	For	For
1.6	Election of Director: Jacquelyn A. Fouse	Management	For	For
1.7	Election of Director: Paul A. Friedman	Management	For	For
1.8	Election of Director: Herve Hoppenot	Management	For	For
2.	To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.	Management	For	For
3.	To approve amendments to the Company's Amended and Restated 2010 Stock Incentive Plan.	Management	For	For
4.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for 2018.	Management	For	For

INNOVIVA INC

Security	45781M101	Meeting Type	Annual
Ticker Symbol	INVA	Meeting Date	24-Apr-2018
Record Date	19-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: George W. Bickerstaff, III	Management	For	For
1b.	Election of Director: Mark DiPaolo, Esq.	Management	For	For
1c.	Election of Director: Jules Haimovitz	Management	For	For
1d.	Election of Director: Odysseas D. Kostas, M.D.	Management	For	For
1e.	Election of Director: Sarah Schlesinger, M.D.	Management	For	For
2.	Approve the non-binding advisory resolution regarding executive compensation.	Management	For	For
3.	Ratify the selection by the Audit Committee of the Board of Directors for Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

INTELLIA THERAPEUTICS, INC.

Security	45826J105	Meeting Type	Annual
-----------------	-----------	---------------------	--------

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Ticker Symbol	NTLA	Meeting Date	17-May-2018
Record Date	04-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Class II Director: Frank Verwiel	Management	For	For
2.	Ratification of the appointment of Deloitte & Touche LLP as Intellia's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

IONIS PHARMACEUTICALS, INC.

Security	462222100	Meeting Type	Annual
Ticker Symbol	IONS	Meeting Date	23-May-2018
Record Date	26-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Frederick T. Muto		For	For
	2 Breaux B. Castleman		For	For
2.	To approve, by non-binding vote, executive compensation.	Management	For	For
3.	Ratify the Audit Committee's selection of Ernst & Young LLP as independent auditors for the 2018 fiscal year.	Management	For	For

JAZZ PHARMACEUTICALS PLC

Security	G50871105	Meeting Type	Annual
Ticker Symbol	JAZZ	Meeting Date	02-Aug-2018
Record Date	06-Jun-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Peter Gray	Management	For	For
1b.	Election of Director: Kenneth W. O Keefe	Management	For	For
1c.	Election of Director: Elmar Schnee	Management	For	For
1d.	Election of Director: Catherine A. Sohn	Management	For	For
2.	To ratify, on a non-binding advisory basis, the appointment of KPMG, Dublin as the independent auditors of Jazz Pharmaceuticals plc for the fiscal year ending December 31, 2018 and to authorize, in a binding vote, the board of directors, acting through the audit committee, to determine the independent auditors remuneration.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of Jazz Pharmaceuticals plc s named executive officers as disclosed in the proxy statement.	Management	For	For
4.	To indicate, on a non-binding advisory basis, the preferred frequency of the advisory vote on the compensation of Jazz Pharmaceuticals plc s named executive officers.	Management	1 Year	For

JOUNCE THERAPEUTICS, INC.

Security	481116101	Meeting Type	Annual
Ticker Symbol	JNCE	Meeting Date	19-Jun-2018
Record Date	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 J. Duncan Higgons		For	For
	2 Robert Tepper, M.D.		For	For
2.	Ratification of the selection of Ernst & Young LLP as the Company s independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

LEXICON PHARMACEUTICALS, INC.

Security	528872302	Meeting Type	Annual
Ticker Symbol	LXRX	Meeting Date	26-Apr-2018
Record Date	26-Feb-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Philippe J. Amouyal	For	For
	2	Lonnell Coats	For	For
	3	Frank P. Palantoni	For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.	Management	For	For
3.	Ratification and approval of the appointment of Ernst & Young LLP as Company's independent auditors for the fiscal year ending December 31, 2018.	Management	For	For

MILESTONE PHARMACEUTICALS INC.

Security	N/A	Meeting Type	Annual
Ticker Symbol	N/A	Meeting Date	27-Jun-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Acceptance of the Audited Financial Statements of the Corporation for year ended December 31, 2017	Management	For	For
2.	Election of Directors	Management	For	For
3.	Appointment of Auditors	Management	For	For
4.	Transaction of other Business	Management	For	For

MOLECULAR TEMPLATES, INC.

Security	608550109	Meeting Type	Annual
Ticker Symbol	MTEM	Meeting Date	31-May-2018
Record Date	10-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jonathan Lanfear		For	For
	2 Scott Morenstein		For	For
2.	Approve the 2018 Equity Incentive Plan.	Management	For	For
3.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending 2018.	Management	For	For
4.	Approve by an advisory vote the compensation of our named executive officers, as disclosed in the accompanying proxy statement.	Management	For	For

MYLAN N.V.

Security	N59465109	Meeting Type	Annual
Ticker Symbol	MYL	Meeting Date	29-Jun-2018
Record Date	01-Jun-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Appointment of Director: Heather Bresch	Management	For	For
1B.	Appointment of Director: Hon. Robert J. Cindrich	Management	For	For
1C.	Appointment of Director: Robert J. Coury	Management	For	For
1D.	Appointment of Director: JoEllen Lyons Dillon	Management	For	For
1E.	Appointment of Director: Neil Dimick, C.P.A.	Management	For	For
1F.	Appointment of Director: Melina Higgins	Management	For	For
1G.	Appointment of Director: Harry A. Korman	Management	For	For
1H.	Appointment of Director: Rajiv Malik	Management	For	For
1I.	Appointment of Director: Mark W. Parrish	Management	For	For
1J.	Appointment of Director: Pauline van der Meer Mohr	Management	For	For
1K.	Appointment of Director: Randall L. (Pete) Vanderveen, Ph.D.	Management	For	For
1L.	Appointment of Director: Sjoerd S. Vollebregt	Management	For	For
2.	Approval, on an advisory basis, of the compensation of the named executive officers of the Company	Management	For	For
3.	Adoption of the Dutch annual accounts for fiscal year 2017	Management	For	For
4.	Ratification of the selection of Deloitte & Touche LLP as the Company's independent registered public accounting firm for fiscal year 2018	Management	For	For
5.	Instruction to Deloitte Accountants B.V. for the audit of the Company's Dutch statutory annual accounts for fiscal year 2018	Management	For	For
6.		Management	For	For

Authorization of the Board to acquire shares in the capital
of the Company

MYOVANT SCIENCES LTD.

Security	G637AM102	Meeting Type	Annual
Ticker Symbol	MYOV	Meeting Date	18-Aug-2017
Record Date	14-Jul-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	ELECTION OF CLASS I DIRECTOR: MARK ALTMAYER	Management	For	For
1.2	ELECTION OF CLASS I DIRECTOR: TERRIE CURRAN	Management	For	For
1.3	ELECTION OF CLASS I DIRECTOR: KEITH MANCHESTER, M.D.	Management	For	For
2.	TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF ERNST & YOUNG LLP AS MYOVANT S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR MYOVANT S FISCAL YEAR ENDING MARCH 31, 2018, TO APPOINT ERNST & YOUNG LLP AS AUDITOR FOR STATUTORY PURPOSES UNDER THE BERMUDA COMPANIES ACT 1981, AS AMENDED, FOR MYOVANT S ...(DUE TO SPACE LIMITS, SEE PROXY STATEMENT FOR FULL PROPOSAL).	Management	For	For

MYOVANT SCIENCES LTD.

Security	G637AM102	Meeting Type	Special
Ticker Symbol	MYOV	Meeting Date	09-Feb-2018
Record Date	22-Jan-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To approve an amendment to our Bye-laws to declassify the Board of Directors.	Management	For	For
2.	To approve an amendment to our Bye-laws to modify shareholder proposal and nomination procedures.	Management	For	For
3.	To approve an amendment to our Bye-laws to eliminate all supermajority voting requirements.	Management	For	For
4.	To approve an amendment to our Bye-laws to modify certain director removal and vacancy requirements.	Management	For	For
5.	To approve an amendment to our Bye-laws to revise certain other provisions in our Bye-laws.	Management	For	For

NABRIVA THERAPEUTICS PLC

Security	G63637105	Meeting Type	Special
Ticker Symbol	NBRV	Meeting Date	15-Sep-2017
Record Date	04-Aug-2017		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: DANIEL BURGESS	Management	For	For
1.2	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: AXEL BOLTE	Management	For	For
1.3	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: CARRIE BOURDOW	Management	For	For
1.4	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: COLIN BROOM	Management	For	For
1.5	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: MARK CORRIGAN	Management	For	For
1.6	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: CHARLES A. ROWLAND, JR.	Management	For	For
1.7	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: GEORGE H. TALBOT	Management	For	For
1.8	ELECTION OF DIRECTOR TO SERVE UNTIL THE 2018 ANNUAL GENERAL MEETING: STEPHEN WEBSTER	Management	For	For
2.	TO RATIFY THE SELECTION OF KPMG LLP AS THE COMPANY S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2017.	Management	For	For
3.	TO APPROVE THE ADOPTION OF THE COMPANY S 2017 SHARE INCENTIVE PLAN.	Management	For	For

NANOSTRING TECHNOLOGIES, INC.

Security	63009R109	Meeting Type	Annual
Ticker Symbol	NSTG	Meeting Date	12-Jun-2018
Record Date	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Elisha W. Finney		For	For
	2 Gregory Norden		For	For
	3 Charles P. Waite		For	For
2.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2018.

NATERA, INC.

Security	632307104	Meeting Type	Annual
Ticker Symbol	NTRA	Meeting Date	16-May-2018
Record Date	26-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Roelof F. Botha	For	For
	2	Todd Cozzens	For	For
	3	Matthew Rabinowitz	For	For
2.	Proposal to ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

NEKTAR THERAPEUTICS

Security	640268108	Meeting Type	Annual
Ticker Symbol	NKTR	Meeting Date	26-Jun-2018
Record Date	27-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Jeff Ajer	Management	For	For
1b.	Election of Director: Robert B. Chess	Management	For	For
1c.	Election of Director: Roy A. Whitfield	Management	For	For
2.	To approve an amendment and restatement of the 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the 2017 Performance Incentive Plan by 10,900,000 shares to a total reserve of 19,200,000 shares.	Management	For	For
3.	To ratify the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
4.	To approve a non-binding advisory resolution regarding our executive compensation (a say-on-pay vote).	Management	For	For

NEUROCRINE BIOSCIENCES, INC.

Security	64125C109	Meeting Type	Annual
Ticker Symbol	NBIX	Meeting Date	24-May-2018
Record Date	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 William H Rastetter PhD		For	For
	2 George J. Morrow		For	For
2.	Advisory vote to approve the compensation paid to the Company's named executive officers.	Management	For	For
3.	To approve an amendment to the Company's 2011 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder from 17,000,000 to 19,000,000.	Management	For	For
4.	To approve the Company's 2018 Employee Stock Purchase Plan.	Management	Against	Against
5.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

NEWLINK GENETICS CORPORATION

Security	651511107	Meeting Type	Annual
Ticker Symbol	NLNK	Meeting Date	23-May-2018

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Record Date 26-Mar-2018

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Chad A. Johnson		For	For
	2 Ernest J. Talarico, III		For	For
	3 Lota S. Zoth		For	For
2.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the proxy statement.	Management	For	For
3.	To indicate, on an advisory basis, the preferred frequency of future advisory votes on the compensation of our named executive officers.	Management	1 Year	For
4.	To ratify the selection, by the Audit Committee of the Board of Directors, of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

NOVAVAX, INC.

Security	670002104	Meeting Type	Annual
Ticker Symbol	NVAX	Meeting Date	14-Jun-2018
Record Date	18-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Richard H. Douglas Ph.D		For	For
	2 Gary C. Evans		For	For
2.	To consider and vote whether to approve, on an advisory basis, the compensation paid to our Named Executive Officers.	Management	For	For
3.	To amend and restate the Novavax, Inc. Amended and Restated 2015 Stock Incentive Plan, as amended, to increase the number of shares of the Company's common stock, par value \$0.01, available for issuance thereunder by 20,000,000 shares.	Management	For	For
4.	To amend and restate the Novavax, Inc. Amended and Restated 2013 Employee Stock Purchase Plan, to increase the number of shares of the Company's common stock, par value \$0.01, available for issuance thereunder by 4,000,000 shares.	Management	For	For
5.	To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

NUCANA PLC

Security	67022C106	Meeting Type	Annual
Ticker Symbol	NCNA	Meeting Date	27-Jun-2018
Record Date	24-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To re-elect (as a Class III director) Isaac Cheng, who is retiring in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O2	To re-elect (as a Class III director) Martin Mellish, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O3	To re-elect (as a Class III director) Adam George, who is retiring by rotation in accordance with the Articles of Association of the Company, as a director of the Company.	Management	For	N/A
O4	To elect (as a Class II director) Cyrille Leperlier, who is standing for election for the remaining portion of his term of office, as a director of the Company.	Management	For	N/A
O5	To re-appoint Ernst & Young LLP as auditors of the Company to hold office from the conclusion of this meeting until the conclusion of the next annual general meeting of the Company.	Management	For	N/A
O6	To authorise the directors to determine the remuneration of the auditors of the Company.	Management	For	N/A
O7	To receive the Company's audited accounts for the financial year ended 31 December 2017, together with the strategic report, directors' report and auditors' report on those accounts.	Management	For	N/A
O8	To receive and approve the Directors' Remuneration Report (other than the part containing the Directors' Remuneration Policy) for the financial year ended 31 December 2017.	Management	For	N/A
O9	To receive and approve the Directors' Remuneration Policy, such policy to take effect from the date on which this resolution is passed.	Management	For	N/A
O10	That the directors be generally and unconditionally authorised pursuant to Section 551 of the Companies Act 2006 (the "Act") to exercise all the powers of the Company to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company up to an aggregate nominal amount of GBP 640,000. This authority shall, unless previously renewed, revoked or varied by the Company in general meeting, expire on the conclusion of the annual general meeting ...(due to space limits, see proxy material for full proposal).	Management	For	N/A
S11	That, subject to the passing of resolution 10, the directors be empowered pursuant to Section 570 of the Act to allot equity securities (as defined in Section 560 of the Act) for cash under the authority given by that resolution as if Section 561 (1) of the Act did not apply to any such allotment, provided that such authority shall be limited to the allotment of equity securities up to a nominal amount of GBP 640,000, such authority to expire on the conclusion of the annual general ...(due to space limits, see proxy	Management	For	N/A

material for full proposal).

OVID THERAPEUTICS INC.

Security	690469101	Meeting Type	Annual
Ticker Symbol	OVID	Meeting Date	06-Jun-2018
Record Date	11-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Douglas Williams		For	For
	2 Barbara Duncan		For	For
2.	Ratification of the selection of the independent registered public accounting firm.	Management	For	For

PIERIS PHARMACEUTICALS, INC.

Security	720795103	Meeting Type	Annual
Ticker Symbol	PIRS	Meeting Date	24-Jul-2018
Record Date	25-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Christopher P. Kiritsy		For	For
	2 Jean-Pierre Bizzari		For	For
2.	Approve the Company's 2018 Employee, Director and Consultant Equity Incentive Plan.	Management	For	For
3.	Approve the Company's 2018 Employee Stock Purchase Plan.	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

PORTOLA PHARMACEUTICALS, INC.

Security	737010108	Meeting Type	Annual
Ticker Symbol	PTLA	Meeting Date	08-Jun-2018
Record Date	12-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Dennis Fenton, Ph.D.		For	For
	2 Charles Homcy, M.D.		For	For
	3 David C. Stump, M.D.		For	For
2.	To approve an amendment to the Company's Amended and Restated Certificate of Incorporation, as amended, to increase the authorized number of shares of common stock from 100,000,000 to 150,000,000 shares.	Management	For	For
3.	To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in this proxy statement.	Management	For	For
4.	To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

PROTAGONIST THERAPEUTICS INC

Security	74366E102	Meeting Type	Annual
Ticker Symbol	PTGX	Meeting Date	29-May-2018
Record Date	09-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Chaitan Khosla, Ph.D.		For	For
	2 William D. Waddill		For	For
	3 Lewis T Williams MD PhD		For	For
2.	To ratify the selection by the Audit Committee of the Board of PricewaterhouseCoopers LLP as Protagonist Therapeutics independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

PTC THERAPEUTICS, INC.

Security	69366J200	Meeting Type	Annual
Ticker Symbol	PTCT	Meeting Date	13-Jun-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Michael Schmertzler		For	For
	2 G D Steele Jr., MD, PhD		For	For
2.	Ratification of the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory vote to approve named executive officer compensation.	Management	For	For

PUMA BIOTECHNOLOGY, INC.

Security	74587V107	Meeting Type	Annual
Ticker Symbol	PBYI	Meeting Date	12-Jun-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Alan H. Auerbach		For	For
	2 Michael P. Miller		For	For
	3 Jay M. Moyes		For	For
	4 Adrian M. Senderowicz		For	For
	5 Troy E. Wilson		For	For
	6 Frank E. Zavrl		For	For
2.	Ratification of the selection of KPMG LLP as independent registered public accounting firm of Puma Biotechnology, Inc. for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of Puma Biotechnology, Inc.'s named executive officers.	Management	For	For
4.	Advisory (non-binding) vote to approve the frequency of future votes on Puma Biotechnology, Inc.'s executive compensation.	Management	1 Year	For

RA PHARMACEUTICALS, INC.

Security	74933V108	Meeting Type	Annual
Ticker Symbol	RARX	Meeting Date	28-Jun-2018
Record Date	30-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Robert Heft, Ph.D.		For	For
	2 Rajeev Shah		For	For
2.	To ratify the appointment of Deloitte & Touche LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

REGENERON PHARMACEUTICALS, INC.

Security	75886F107	Meeting Type	Annual
Ticker Symbol	REGN	Meeting Date	08-Jun-2018
Record Date	12-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Arthur F. Ryan	Management	For	For
1.2	Election of Director: George L. Sing	Management	For	For
1.3	Election of Director: Marc Tessier-Lavigne	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

REVANCE THERAPEUTICS, INC.

Security	761330109	Meeting Type	Annual
Ticker Symbol	RVNC	Meeting Date	10-May-2018
Record Date	13-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Angus C. Russell	Management	For	For
1b.	Election of Director: Phyllis Gardner, M.D.	Management	For	For
1c.	Election of Director: Julian S. Gangolli	Management	For	For
2.	Ratification of the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year 2018.	Management	For	For

SAGE THERAPEUTICS, INC.

Security	78667J108	Meeting Type	Annual
Ticker Symbol	SAGE	Meeting Date	06-Jun-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Geno Germano		For	For
	2 Steven Paul		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Approve, on an advisory basis, the compensation of the named executive officers.	Management	For	For

SAREPTA THERAPEUTICS INC.

Security	803607100	Meeting Type	Annual
Ticker Symbol	SRPT	Meeting Date	06-Jun-2018
Record Date	11-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A	ELECTION OF GROUP I DIRECTOR: Michael W. Bonney	Management	For	For
1B	ELECTION OF GROUP I DIRECTOR: Douglas S. Ingram	Management	For	For
1C	ELECTION OF GROUP I DIRECTOR: Hans Wigzell, M.D., Ph.D.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

2.	ADVISORY VOTE TO APPROVE, ON A NON-BINDING BASIS, NAMED EXECUTIVE OFFICER COMPENSATION	Management	For	For
3.	APPROVAL OF THE COMPANY S 2018 EQUITY INCENTIVE PLAN	Management	For	For
4.	RATIFICATION OF KPMG LLP AS INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2018	Management	For	For

SEATTLE GENETICS, INC.

Security	812578102	Meeting Type	Annual
Ticker Symbol	SGEN	Meeting Date	18-May-2018
Record Date	22-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Clay B. Siegall		For	For
	2 Felix Baker		For	For
	3 Nancy A. Simonian		For	For
2.	To ratify the appointment of PricewaterhouseCoopers LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve the amendment and restatement of the Seattle Genetics, Inc. Amended and Restated 2007 Equity and Incentive Plan to, among other changes, increase the aggregate number of shares of common stock authorized for issuance thereunder by 6,000,000.	Management	For	For
4.	Advisory vote to approve the compensation of the Company's named executive officers as disclosed in the Company's proxy statement.	Management	For	For

SHIRE PLC

Security	82481R106	Meeting Type	Annual
Ticker Symbol	SHPG	Meeting Date	24-Apr-2018
Record Date	22-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	To receive the Company's Annual Report and Accounts for the year ended December 31, 2017.	Management	For	For
2.	To approve the Directors' Remuneration Report, excluding the Directors' Remuneration Policy, set out on pages 78 to 108 of the Annual Report and Accounts for the year ended December 31, 2017.	Management	For	For
3.	To approve the Directors' Remuneration Policy, contained within the Directors' Remuneration Report and set out on pages 86 to 95 of the Annual Report and Accounts for the year ended December 31, 2017, to take effect after the end of the Annual General Meeting on April 24, 2018.	Management	For	For
4.	To re-elect Olivier Bohuon as a Director.	Management	For	For
5.	To re-elect Ian Clark as a Director.	Management	For	For
6.	To elect Thomas Dittrich as a Director.	Management	For	For
7.	To re-elect Gail Fosler as a Director.	Management	For	For
8.	To re-elect Steven Gillis as a Director.	Management	For	For
9.	To re-elect David Ginsburg as a Director.	Management	For	For
10.	To re-elect Susan Kilsby as a Director.	Management	For	For
11.	To re-elect Sara Mathew as a Director.	Management	For	For
12.	To re-elect Flemming Ornskov as a Director.	Management	For	For
13.	To re-elect Albert Stroucken as a Director.	Management	For	For
14.	To re-appoint Deloitte LLP as the Company's Auditor until the conclusion of the next Annual General Meeting of the Company.	Management	For	For
15.	To authorize the Audit, Compliance & Risk Committee to determine the remuneration of the Auditor.	Management	For	For
16.	That the authority to allot Relevant Securities (as defined in the Company's Articles of Association (the "Articles")) conferred on the Directors by Article 10 paragraph (B) of the Articles be renewed and for this purpose the Authorised Allotment Amount shall be: (a) GBP 15,187,600.85 of Relevant Securities. (b) solely in connection with an allotment pursuant to an offer by way of a Rights Issue (as defined in the Articles, but only if and to the extent that such offer is ...(due to space limits, see proxy material for full proposal).	Management	For	For
17.	That, subject to the passing of Resolution 16, the authority to allot equity securities (as defined in the Company's Articles of Association (the "Articles")) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles be renewed and for this purpose the Non Pre-emptive Amount (as defined in the Articles) shall be GBP 2,278,140.10 and the Allotment Period shall be the period commencing on April 24, 2018, and ending on the earlier of the close of business on ...(due to space limits, see proxy material for full proposal).	Management	For	For
18.		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

That, subject to the passing of Resolutions 16 and 17 and for the purpose of the authority to allot equity securities (as defined in the Company's Articles of Association (the Articles)) wholly for cash conferred on the Directors by Article 10 paragraph (D) of the Articles and renewed by Resolution 17, the Non Pre-emptive Amount (as defined in the Articles) shall be increased from GBP 2,278,140.10 to GBP ...(due to space limits, see proxy material for full proposal).

19.	That the Company be and is hereby generally and unconditionally authorized: (a) pursuant to Article 57 of the Companies (Jersey) Law 1991 to make market purchases of Ordinary Shares in the capital of the Company, provided that: (1) the maximum number of Ordinary Shares hereby authorized to be purchased is 91,125,605; (2) the minimum price, exclusive of any expenses, which may be paid for an Ordinary Share is five pence; (3) the maximum price, exclusive of any expenses, which may be paid ...(due to space limits, see proxy material for full proposal).	Management	For	For
20.	To approve that a general meeting of the Company, other than an annual general meeting, may be called on not less than 14 clear days' notice.	Management	For	For

SPARK THERAPEUTICS, INC.

Security	84652J103	Meeting Type	Annual
Ticker Symbol	ONCE	Meeting Date	30-May-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jeffrey D. Marrazzo		For	For
	2 Vincent J. Milano		For	For
	3 Elliott Sigal M.D. Ph.D		For	For
2.	To approve, on an advisory basis, the compensation paid to the Company's named executive officers.	Management	For	For
3.	To ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

SYNDAX PHARMACEUTICALS, INC

Security	87164F105	Meeting Type	Annual
Ticker Symbol	SNDX	Meeting Date	23-May-2018
Record Date	26-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Henry Chen	Management	For	For
1b.	Election of Director: Luke Evnin, Ph.D.	Management	For	For
2.	To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2018.	Management	For	For

TELIGENT, INC.

Security	87960W104	Meeting Type	Annual
Ticker Symbol	TLGT	Meeting Date	21-May-2018
Record Date	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Carole S. Ben-Maimon		For	For
	2 John Celentano		For	For
	3 Bhaskar Chaudhuri		For	For
	4 James C. Gale		For	For
	5 Jason Grenfell-Gardner		For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

	6	Steven Koehler		For	For
	7	Thomas J. Sabatino, Jr.		For	For
2.		Approve an amendment to the Teligent, Inc. 2016 Equity Incentive Plan to increase the number of shares of common stock reserved thereunder for issuance from 2,000,000 shares to a total of 4,000,000 shares.	Management	For	For
3.		To ratify the selection of EisnerAmper LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
4.		To approve by an advisory vote the compensation of the Company's named executive officers as disclosed in the proxy statement.	Management	For	For

TESARO INC

Security	881569107	Meeting Type	Annual
Ticker Symbol	TSRO	Meeting Date	10-May-2018
Record Date	13-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Leon O. Moulder, Jr.		For	For
	2 Mary Lynne Hedley, Ph.D		For	For
	3 David M. Mott		For	For
	4 Lawrence M. Alleva		For	For
	5 James O. Armitage, M.D.		For	For
	6 Earl M. Collier, Jr.		For	For
	7 Garry A. Nicholson		For	For
	8 Kavita Patel, M.D.		For	For
	9 Beth Seidenberg, M.D.		For	For
	10 Pascale Witz		For	For
2.	To approve the Tesaro, Inc., Non-Employee Director Compensation Policy, including compensation amounts for 2018.	Management	For	For
3.	To approve, by non-binding vote, the Company's executive compensation.	Management	For	For
4.	To approve an amendment to the Tesaro, Inc., 2012 Employee Stock Purchase Plan to, among other things, increase the number of shares available for issuance thereunder by 275,000 shares.	Management	For	For
5.	To ratify the appointment of Ernst & Young, LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2018.	Management	For	For

TETRAPHASE PHARMACEUTICALS, INC.

Security	88165N105	Meeting Type	Annual
Ticker Symbol	TTPH	Meeting Date	30-May-2018
Record Date	06-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Jeffrey Chodakewitz		For	For
	2 Gerri Henwood		For	For
	3 Guy Macdonald		For	For
2.	To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	To approve, on a non-binding advisory basis, the compensation of our named executive officers.	Management	For	For

THE MEDICINES COMPANY

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	584688105	Meeting Type	Annual
Ticker Symbol	MDCO	Meeting Date	31-May-2018
Record Date	13-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Alexander J. Denner	Management	For	For
1B.	Election of Director: Fredric N. Eshelman	Management	For	For
1C.	Election of Director: Geno J. Germano	Management	For	For
1D.	Election of Director: John C. Kelly	Management	For	For
1E.	Election of Director: Clive A. Meanwell	Management	For	For
1F.	Election of Director: Paris Panayiotopoulos	Management	For	For
1G.	Election of Director: Sarah J. Schlesinger	Management	For	For
2.	Approve an amendment to our 2013 stock incentive plan in order to increase the number of shares of common stock authorized for issuance under the plan by 5,000,000 shares.	Management	For	For
3.	Approve, in an advisory vote, the compensation of our named executive officers as presented in the proxy statement.	Management	For	For
4.	Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

THERAPEUTICSMD, INC.

Security	88338N107	Meeting Type	Annual
Ticker Symbol	TXMD	Meeting Date	25-Jun-2018
Record Date	26-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1 Tommy G. Thompson		For	For
	2 Robert G. Finizio		For	For
	3 John C.K. Milligan, IV		For	For
	4 Brian Bernick		For	For
	5 J. Martin Carroll		For	For
	6 Cooper C. Collins		For	For
	7 Robert V. LaPenta, Jr.		For	For
	8 Jules A. Musing		For	For
	9 Angus C. Russell		For	For
	10 Jane F. Barlow		For	For
	11 Nicholas Segal		For	For
2.	To approve, on a non-binding advisory basis, the compensation of our named executive officers for the fiscal year ended December 31, 2017 (say-on-pay).	Management	For	For
3.	To ratify the appointment of Grant Thornton LLP, an independent registered public accounting firm, as the independent auditor of our company for the fiscal year ending December 31, 2018.	Management	For	For

THERAVANCE BIOPHARMA, INC.

Security	G8807B106	Meeting Type	Annual
Ticker Symbol	TBPH	Meeting Date	01-May-2018
Record Date	05-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Director: Eran Broshty	Management	For	For
1.2	Election of Director: Laurie Smaldone Alsup	Management	For	For
1.3	Election of Director: Burton G. Malkiel	Management	For	For
2.	Ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Adoption of the resolution approving a new shareholder rights plan and authorizing our board of directors to put the shareholder rights plan into effect in the future if and when the board of directors deems appropriate and in the best interests of the Company, which resolution is set forth as Annex A to the proxy statement.	Management	For	For

THERMO FISHER SCIENTIFIC INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	883556102	Meeting Type	Annual
Ticker Symbol	TMO	Meeting Date	23-May-2018
Record Date	28-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1A.	Election of Director: Marc N. Casper	Management	For	For
1B.	Election of Director: Nelson J. Chai	Management	For	For
1C.	Election of Director: C. Martin Harris	Management	For	For
1D.	Election of Director: Tyler Jacks	Management	For	For
1E.	Election of Director: Judy C. Lewent	Management	For	For
1F.	Election of Director: Thomas J. Lynch	Management	For	For
1G.	Election of Director: Jim P. Manzi	Management	For	For
1H.	Election of Director: Lars R. Sorensen	Management	For	For
1I.	Election of Director: Scott M. Sperling	Management	For	For
1J.	Election of Director: Elaine S. Ullian	Management	For	For
1K.	Election of Director: Dion J. Weisler	Management	For	For
2.	An advisory vote to approve named executive officer compensation.	Management	For	For
3.	Ratification of the Audit Committee's selection of PricewaterhouseCoopers LLP as the Company's independent auditors for 2018.	Management	For	For

THEROX, INC.

Security	N/A	Meeting Type	Written Consent
Ticker Symbol	N/A	Meeting Date	24-Apr-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Approval of Second Certificate of Amendment to Eleventh Amended and Restated Certificate of Incorporation	Management	For	For
2.	Waiver of Participation Rights in Note Transaction	Management	For	For
3.	Approval of Amendment to Fourth Amended and Restated Investors Rights and Voting Agreement	Management	For	For
4.	Approval of Option Agreement with ZOLL	Management	For	For
5.	Approval of Agreement and Plan of Merger	Management	For	For
6.	Appointment of Shareholder Representative Services, LLC as Representative	Management	For	For
7.	Appointment of Representative Advisory Group Members	Shareholder	Against	For
8.	Ratification of Shadow Preferred Stock Issuance	Shareholder	Against	For
9.	General Authority	Shareholder	Against	For

TRILLIUM THERAPEUTICS INC.

Security	89620X506	Meeting Type	Annual and Special Meeting
Ticker Symbol	TRIL	Meeting Date	01-Jun-2018
Record Date	20-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1	DIRECTOR	Management		
	1 Mr. Luke Beshar		For	For
	2 Dr. Robert Kirkman		For	For
	3 Dr. Michael Moore		For	For
	4 Dr. Thomas Reynolds		For	For
	5 Dr. Niclas Stiernholm		For	For
	6 Dr. Calvin Stiller		For	For
	7 Dr. Helen Tayton-Martin		For	For
2	To reappoint Ernst & Young, LLP, Chartered Professional Accountants, Licensed Public Accountants, as auditors of the Corporation for the ensuing year and to authorize the directors to fix the remuneration to be paid to the auditors.	Management	For	For
3	Consider and, if deemed appropriate, approve the Corporation s amended and restated stock option plan, all as more particularly set out in the management information circular prepared by the Corporation in respect of the Meeting.	Management	Against	Against

ULTRAGENYX PHARMACEUTICAL INC.

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Security	90400D108	Meeting Type	Annual
Ticker Symbol	RARE	Meeting Date	19-Jun-2018
Record Date	23-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Deborah Dunsire, M.D.	Management	For	For
1b.	Election of Director: Michael Narachi	Management	For	For
1c.	Election of Director: Clay B. Siegall, Ph.D.	Management	For	For
2.	Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018.	Management	For	For
3.	Advisory (non-binding) vote to approve the compensation of our named executive officers.	Management	For	For

UNIQUE N.V.

Security	N90064101	Meeting Type	Annual
Ticker Symbol	QURE	Meeting Date	13-Jun-2018
Record Date	16-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	Resolution to adopt the 2017 annual accounts and treatment of the results.	Management	For	For
2.	Resolution to discharge liability of the members of the Board for their management.	Management	For	For
3a.	Appointment of Philip Astley-Sparke as non-executive director.	Management	For	For
3b.	Appointment of Robert Gut as non-executive director.	Management	For	For
3c.	Appointment of David Meek as non-executive director.	Management	For	For
4.	Amendment to the 2014 Restated Plan.	Management	For	For
5.	Resolution to designate the Board as the competent body to issue ordinary shares and options and to exclude preemptive rights under the 2014 Restated Plan.	Management	For	For
6.	Approval of the employee share purchase plan.	Management	For	For
7.	Resolution to redesignate the Board as the competent body to issue ordinary shares and options and to limit or exclude pre-emptive rights.	Management	For	For
8.	Authorization of the Board to repurchase ordinary shares.	Management	For	For
9.	Resolution to reappoint PricewaterhouseCoopers Accountants N.V. as auditor of the Company for the 2018 financial year ending at the close of the Annual General Meeting.	Management	For	For

UNITED THERAPEUTICS CORPORATION

Security	91307C102	Meeting Type	Annual
Ticker Symbol	UTHR	Meeting Date	26-Jun-2018
Record Date	30-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1a.	Election of Director: Katherine Klein	Management	For	For
1b.	Election of Director: Ray Kurzweil	Management	For	For
1c.	Election of Director: Martine Rothblatt	Management	For	For
1d.	Election of Director: Louis Sullivan	Management	For	For
2.	Advisory resolution to approve executive compensation.	Management	For	For
3.	Approval of the amendment and restatement of the United Therapeutics Corporation 2015 Stock Incentive Plan.	Management	For	For
4.	Ratification of the appointment of Ernst & Young LLP as United Therapeutics Corporation's independent registered public accounting firm for 2018.	Management	For	For

VERONA PHARMA PLC

Security	GB00BYW2KH80	Meeting Type	Annual General Meeting
Ticker Symbol	VRP	Meeting Date	02-May-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	TO RECEIVE AND ADOPT THE REPORT OF THE DIRECTORS AND THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2017	Management	For	For
2	TO APPROVE THE DIRECTORS REMUNERATION POLICY	Management	For	For
3	TO APPROVE THE DIRECTORS REMUNERATION REPORT	Management	For	For
4	TO RE-ELECT DAVID RAYMOND EBSWORTH AS A DIRECTOR OF THE COMPANY	Management	For	For
5	TO RE-ELECT SVEN ANDERS ULLMAN AS A DIRECTOR OF THE COMPANY	Management	For	For
6	TO APPOINT PRICEWATERHOUSECOOPERS LLP AS AUDITORS	Management	For	For
7	TO AUTHORISE THE DIRECTORS TO DETERMINE THE AUDITORS REMUNERATION	Management	For	For
8	TO AUTHORISE THE DIRECTORS TO ALLOT RELEVANT SECURITIES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006	Management	For	For
9	TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES PURSUANT TO SECTION 570 OF THE COMPANIES ACT 2006	Management	For	For

VERONA PHARMA PLC

Security	925050106	Meeting Type	Annual
Ticker Symbol	VRNA	Meeting Date	02-May-2018
Record Date	06-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
O1	To receive and adopt the report of the directors and the financial statements for the year ended 31 December 2017.	Management	For	For
O2	To approve the Directors Remuneration Policy.	Management	For	For
O3	To approve the Directors Remuneration Report.	Management	For	For
O4	To re-elect David Raymond Ebsworth as a director of the Company.	Management	For	For
O5	To re-elect Sven Anders Ullman as a director of the Company.	Management	For	For
O6	To appoint PricewaterhouseCoopers LLP as auditors.	Management	For	For
O7	To authorise the directors to determine the auditors remuneration.	Management	For	For
O8		Management	For	For

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.

S9	To authorise the directors to allot equity securities pursuant to Section 570 of the Companies Act 2006.	Management	For	For
----	--	------------	-----	-----

VERONA PHARMA PLC

Security	GB00BYW2KH80	Meeting Type	Ordinary General Meeting
Ticker Symbol	VRP	Meeting Date	26-Jun-2018
Record Date	N/A		

Item	Proposal	Proposed by	Vote	For/Against Management
1	TO AUTHORISE THE DIRECTORS TO ALLOT RELEVANT SECURITIES PURSUANT TO SECTION 551 OF THE COMPANIES ACT 2006	Management	For	For
2	TO AUTHORISE THE DIRECTORS TO ALLOT EQUITY SECURITIES AND/OR SELL TREASURY SECURITIES FOR CASH PURSUANT TO SECTION 570 AND 573 OF THE COMPANIES ACT 2006	Management	For	For

VERONA PHARMA PLC

Security	925050106	Meeting Type	Annual
Ticker Symbol	VRNA	Meeting Date	26-Jun-2018
Record Date	24-May-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
O1.	To authorise the directors to allot relevant securities pursuant to Section 551 of the Companies Act 2006.	Management	For	For
S2.	To authorise the directors to allot equity securities and/or sell treasury securities for cash pursuant to Section 570 and 573 of the Companies Act 2006.	Management	For	For

VERTEX PHARMACEUTICALS INCORPORATED

Security	92532F100	Meeting Type	Annual
Ticker Symbol	VRTX	Meeting Date	17-May-2018
Record Date	29-Mar-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.1	Election of Class I Director: Sangeeta N. Bhatia	Management	For	For
1.2	Election of Class I Director: Jeffrey M. Leiden	Management	For	For
1.3	Election of Class I Director: Bruce I. Sachs	Management	For	For
2.	Amendments to our charter and by-laws to eliminate supermajority provisions.	Management	For	For
3.	Amendment and restatement of our 2013 Stock and Option Plan, to among other things, increase the number of shares available under the plan by 8.0 million shares.	Management	For	For
4.	Ratification of Ernst & Young LLP as our Independent Registered Public Accounting firm for the year ending December 31, 2018.	Management	For	For
5.	Advisory vote on named executive officer compensation.	Management	For	For
6.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on the risks to us of rising drug prices.	Shareholder	Against	For
7.	Shareholder proposal, if properly presented at the meeting, requesting that we prepare a report on our policies and activities with respect to lobbying.	Shareholder	Against	For

XENCOR INC

Security	98401F105	Meeting Type	Annual
Ticker Symbol	XNCR	Meeting Date	26-Jun-2018
Record Date	27-Apr-2018		

Edgar Filing: TEKLA LIFE SCIENCES INVESTORS - Form N-PX

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Dr. Kevin C. Gorman	For	For
	2	Dr. A. Bruce Montgomery	For	For
	3	Dr. Bassil I. Dahiyat	For	For
	4	Mr. Kurt Gustafson	For	For
	5	Mr. Yujiro S. Hata	For	For
	6	Mr. Richard Ranieri	For	For
2.	Proposal to ratify RSM US LLP as the independent public accounting firm for 2018.	Management	For	For
3.	Proposal to approve, on an advisory basis, the compensation of the Company's named executive officers as disclosed in the proxy materials.	Management	For	For

XENON PHARMACEUTICALS INC

Security	98420N105	Meeting Type	Annual
Ticker Symbol	XENE	Meeting Date	04-Jun-2018
Record Date	09-Apr-2018		

Item	Proposal	Proposed by	Vote	For/Against Management
1.	DIRECTOR	Management		
	1	Michael Tarnow	For	For
	2	Mohammad Azab	For	For
	3	Steven Gannon	For	For
	4	Michael Hayden	For	For
	5	Frank Holler	For	For
	6	Gary Patou	For	For
	7	Simon Pimstone	For	For
	8	Richard Scheller	For	For
	9	Dawn Svoronos	For	For
2.	Appointment of KPMG LLP as Auditor	Management	For	For
3.	Authorizing the Audit Committee of the board of directors of the Corporation to fix the remuneration to be paid to the Auditor	Management	For	For

SIGNATURES

Pursuant to the requirements of the Investment Company Act of 1940, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

(Registrant) Tekla Life Sciences Investors

By (Signature and Title)*

/s/ Daniel R. Omstead
(Daniel R. Omstead, President)

Date 8/20/18

*Print the name and title of each signing officer under his or her signature.